Development of a high-speed capillary electrophoresis assay for the analysis of branched chain amino acids released from 3T3-L1 adipocytes by Harstad, Rachel
  
 
 
 
 
Development of a high-speed capillary electrophoresis assay for the analysis of branched 
chain amino acids released from 3T3-L1 adipocytes 
 
 
 
 
A THESIS 
SUBMITTED TO THE FACULTY OF 
UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
Rachel Kay Harstad 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
Michael T. Bowser, Advisor 
 
 
 
 
August 2016 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Rachel Kay Harstad, 2016 
 
  i 
Acknowledgements 
I would like to start by thanking my graduate school research advisor, Dr. 
Michael T. Bowser, for the inspiration and guidance that he has provided throughout my 
career as a graduate student. Joining his research group was the best choice I made 
entering graduate school and I am so very thankful for the opportunity to be a part of the 
exciting research going on in the Bowser Lab. Through this research, I was able to 
develop skills and learn life lessons that are needed to for success in the future—not only 
as a scientist, but in everyday life. Thank you. 
I would like to thank my fellow Bowser group members that I’ve had the pleasure 
of working with over the past 5 years, especially Jing Yang, Thane Taylor, Amy Stading, 
Matt Geiger, Sarah Anciaux, Megan Weisenberger, Kailey Soller, Alex Johnson, and 
Sean Dembowski. Thank you all for all of the meaningful (and not so meaningful) 
conversations we’ve had over the years. Thanks for making the lab a place that I want to 
come back to everyday. 
I would like to thank my professors at the University of Minnesota that I’ve had 
the pleasure of interacting with during my time as a student here. I would also like to 
thank the labs of Dr. Edgar Arriaga and Dr. Christy Haynes, for guidance early on in my 
graduate career, with techniques our lab was unfamiliar with at the time.  
I would like to thank my friends that have always been there for me, whenever I 
needed a listening ear or a break from reality. All of you have helped shape who I am as a 
person and I thank you for all the memories we have created over the years.  
  ii 
And last, but certainly not least, I would like to thank my parents, Tom and Sue, 
for your never ending support and encouragement. Without your support, especially 
while growing up, I wouldn’t have learned to strive to always do my best, and do my best 
no matter what. Thank you for showing me that hard work does pay-off; without this 
valuable skill, graduate school would have been nearly impossible to get through. I am 
forever grateful for your love and support.  
  iii 
 
 
 
 
 
 
 
Dedicated to my parents and sister:  
for their love and support throughout my education.  
  iv 
Abstract 
 
We have developed a high-throughput assay for monitoring branched chain amino 
acid (BCAA) uptake and release dynamics in 3T3-L1 cells using microdialysis coupled to 
high speed capillary electrophoresis (CE). Isoleucine, leucine, and valine are important 
indicators of lipogenesis, as are alanine, glutamate, and glutamine, which are by-products 
produced through the catabolism of BCAAs. The major focus of this work will be on the 
development and optimization of a high-speed (high-throughput) CE assay for the 
separation of fluorescently labeled amino acids; particularly the BCAAs and their 
downstream metabolites. Development of this assay allows for us to ask important 
biological questions related to lipogenesis using an in vitro cell model. In combination 
with bulk culture, release and uptake rates of BCAAs were monitored and assessed as a 
function of various biological stimuli, including several concentrations of glucose, 
circulating concentrations of BCAAs, as well as insulin and artificial sweeteners. 
Changes in release profiles were also monitored as cells progressed through the 
differentiation cycle in order to see if development stage affects lipogenesis.  
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 Motivation and Cell Models 1.1
 Obesity 1.1.1
Obesity rates worldwide have more than doubled since 1980; more than 1.9 
billion adults are overweight and over 600 million adults are obese as of 2014.
1
 Because 
this disorder has reached unprecedented levels, recent research has focused on 
understanding how obesity develops and progresses. For many overweight patients, a 
simple change in energy flux is not enough to reverse the acquired problems. Once basic 
principles about how obesity develops are understood, we can work to develop methods 
for prevention and treatment, when diet and exercise are not enough to counteract 
negative symptoms. Understanding connections between our daily energy intake and 
development of obesity will also offer insight into the mechanisms of disease 
development.  
The role of adipose tissue in obesity has been scrutinized over the past several 
decades. For many years, adipose tissue was thought to act only as a storage depot for 
excess energy taken in during meal consumption.
2,3
 Recently, however, it was discovered 
that adipose tissue acts as an endocrine organ, signaling to other organs to give 
information about energy balance, appetite, and inflammation.
4-9
 In order to understand 
this signaling mechanism and how it contributes to the development of obesity, it is 
important to understand the role of adipose tissue throughout the body. 
There are two types of adipose tissue found in the body—brown and white (BAT, 
WAT, respectively).
10,11
 Both BAT and WAT store excess energy as triglycerides in lipid 
vesicles; however, they are much different in appearance. BAT typically has a single, 
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large lipid vesicle, while WAT has many smaller lipid vesicles. BAT’s role in the body is 
much different than WAT. BAT is the source of thermogenesis,
12,13
while WAT is 
traditionally thought to be primarily used for longer term storage, housing triglycerides 
until they are mobilized for use in gluconeogenesis.
2,3
 Recently, WAT been shown to 
release small molecule messengers that play an important role in signaling throughout the 
body including signaling to the pancreas, muscle, and the brain.
14-16
  
Those who are overweight or obese have an increased percentage of WAT 
throughout the body as compared to lean muscle mass. This increase can be attributed to 
expansion of adipocytes from increased lipid storage, as well as an increase in the 
number of total adipocytes. Humans who are obese have a higher total adipocyte number 
than lean individuals.
5,17,18
 Recently, it was discovered that new adipocytes can be formed 
throughout life,
17
 however, it is not well understood what contributes more to obesity, 
adipocyte size or number.  
Due to expansion of the adipose tissue, the cells undergo molecular changes in 
metabolism. These changes include physical expansion of the adipocytes, increased free 
fatty acid release from adipocytes, and increased production and release of inflammatory 
and other energy regulating hormones.
5
 Physical expansion of both individual cells, as 
well as adipose tissue, may play a critical role in the development of disease and cellular 
dysfunction.
5
 Excess adipose tissue, as seen in those who are obese, has been linked to 
type-2 diabetes, heart disease, high blood pressure, and can lead to increased risk of 
development for many types of cancers, including breast cancer and colon cancer.
5
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Adipocytes secrete many hormones and cytokines that serve as signaling 
messengers throughout the body.
4,8,9,19,20
 Having excess adipose tissue oftentimes causes 
patients to develop resistance to insulin and leptin, two hormones important for 
regulation of energy balance.
4,5,8,21,22
 Dysregulation of the secretion of these hormones, 
along with the small molecules released, may play an important role in the development 
of obesity and other metabolic diseases.
23
  
 Branched Chain Amino Acids 1.1.2
The branched chain amino acids (BCAAs), isoleucine, leucine, and valine (Figure 
1.1) are important signaling molecules throughout the body. BCAAs have been identified 
as an important group of small molecules regulated by adipocytes. These BCAAs are 
essential amino acids and not easily metabolized by the liver.
24
 There is evidence to 
suggest that these amino acids in particular, play a role in the development of obesity and 
obesity related diseases.
25
 BCAA receptors can be found throughout the body and 
BCAAs are highly regulated in adipose tissue. Adipose tissue regulates whole body 
BCAA concentrations as a signal to other organs about the state of energy balance in 
adipose.
26-29
  
Figure 1.1. Molecular structures of the branched chain amino acids. 
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BCAAs are controlled in adipose tissue through catabolism, which feeds into the 
lipogenesis cycle and the production of tricarboxylic acid (TCA) cycle or fatty acid 
synthesis intermediates (Figure 1.2).
26-29
 Recent studies have shown that 3T3-L1 cells 
catabolize isoleucine and leucine to generate nearly one-third of the acetyl-CoA used in 
the TCA cycle.
30
 When energy is readily available, excess energy is stored as 
triglycerides in lipid vesicles, where it can be easily mobilized when cellular energy is 
low.  
It is known that BCAAs are found in higher concentrations in those who are 
overweight and obese.
26-28
 It has also been shown that leucine stimulates the release of 
leptin from adipocytes.
31-33
 Overstimulation of the adipocytes, thus, increased release of 
Figure 1.2. Pathways involved in the catabolism of BCAAs. BCAAs + α-
ketoglutarate (α-KG) produces branched chain keto-acids (BCKAs) and 
glutamate. The BCKAs are further metabolized to acetyl-CoA, where it either 
goes to the TCA cycle or fatty acid synthesis pathways, depending on the cell’s 
energy needs. 
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leptin from adipocytes, may lead to the development of resistance to this important 
hormone. In addition to leucine, it has also been shown that high concentrations of 
glucose and L-alanine influence leptin release from adipocytes.
25,32
  
 Obesity Models 1.1.3
Obesity can be studied in vitro or in vivo, using many different cell and animal 
models, including human patients.
34-37
 While both in vitro and in vivo models have their 
distinct advantages and disadvantages, an in vitro design is simple and allows for basic 
knowledge discovery. 3T3-L1 and 3T3-F442A cell lines are the two most popular models 
used for studying obesity in vitro.
38
 The 3T3-L1 cell line was isolated from parent mouse 
3T3 cultures after identifying colonies with a lipid accumulating phenotype once cells 
reached confluency.
39
 Previously, Thomson et al. used 3T3-L1 cells to study the 
development of insulin resistance,
40
 while Tremblay et al. used 3T3-L1 cells to study 
activation of the mammalian target of rapamycin (mTOR) pathway and its effects on 
insulin signaling.
41
 More recently, 3T3-L1 cells were used to study the catabolism of 
BCAAs and their corresponding contribution to odd or even-chain fatty acids.
42
 
Differentiation is fairly straightforward and has been optimized in order to achieve full 
differentiation into mature adipocytes.
43,44
 
 Microdialysis 1.2
 Microdialysis Probe Design and Function 1.2.1
Microdialysis probes are created by sealing two capillaries inside of a regenerated 
cellulose, hollow fiber dialysis membrane, in either a side-by-side, concentric, loop, or 
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linear arrangement.
45
 Figure 1.3 shows the side-by-
side configuration of a microdialysis probe. The 
hollow fiber tubing is porous and acts as a membrane 
that filters out large, complex biological samples, 
only allowing molecules with molecular weights less 
than the molecular weight cut off (MWCO) to diffuse 
through. Hollow fiber dialysis tubing is available with 
various MWCO thresholds, in order to be used with a 
wide variety of target substrates.  
This probe is most often inserted into the 
tissue of interest and perfused with a solution that 
closely matches the surrounding extra-cellular matrix, 
called perfusate. The perfusate flows in through the 
inlet capillary (Figure 1.3, A). Analytes present in the 
tissue diffuse across the dialysis membrane, and are 
recovered. Perfusate flowing in through the inlet 
capillary pushes the solution out of the sampling 
region and out through the outlet capillary (Figure 
1.3, B). This outlet stream, termed dialysate, is moved 
out of the capillary and contains a fraction of the molecules present in the extracellular 
matrix and can be used for analysis. Perfusate is pushed through the capillaries at very 
Figure 1.3. Side-by-side 
microdialysis probe. Perfusate is 
pushed through capillary A. 
Small molecules diffuse from the 
extracellular space through the 
membrane into the perfusate. The 
perfusate is then pushed out 
through capillary B, as dialysate. 
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low flow rates to ensure small molecules 
move across the membrane based on the 
concentration gradient.
46
  
 Recovery and Resolution 1.2.2
Absolute quantification of 
analytes in tissues is difficult when using 
microdialysis sampling. Equilibrium 
between the perfusate and surrounding 
cellular matrix is never established 
because the perfusate is constantly being pushed through the microdialysis probe, even at 
typical, slow flow rates (0.1-1 µL/min). Thus, concentrations of recovered analytes 
collected are proportional to each other, but are a fraction of the actual concentrations 
found in the tissue matrix.
45,47-49
  
In order to quantitatively determine analytes present in the tissue matrix, recovery 
rates for each probe must be established. Under the assumptions that the concentration 
outside of the probe is proportional to the concentration in the dialysate, the recovery can 
be determined under a set of experimental conditions. There are two types of recovery 
commonly associated with microdialysis: relative recovery and absolute recovery.
50
 
Absolute recovery is a rate indicating how much analyte is recovered per a given amount 
of time. Relative recovery compares the concentration of analytes in a solution that have 
diffused through a probe to the concentration of analytes in the same solution when that 
solution is pumped directly into the analytical detection method. These recoveries are 
Figure 1.4. Relative and absolute recoveries 
for a microdialysis probe, plotted as a 
function of flow rate. Adapted from 
Reference 51. 
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sensitive to the flow rate of perfusate through the microdialysis probe. As higher flow 
rates through the microdialysis probe are used, absolute recovery increases, while relative 
recovery decreases, as shown in Figure 1.4.
51
 Peak heights of each analyte are compared 
to determine the relative recovery of the corresponding analyte.
52
 The extraction 
efficiency is the ratio between gain of analytes in the dialysate and loss of analyte from 
the surrounding matrix:  
𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
C𝑑− 𝐶𝑖
C𝑒−𝐶𝑖
  (1.1) 
where Cd is the concentration of analyte in the dialysate, Ci is the concentration in the 
perfusate, and Ce is the concentration in the surrounding matrix. Ci=0 (essentially) when 
performing recovery experiments, and thus, the extraction efficiency becomes identical to 
the relative recovery. The following equation (1.2) has been widely accepted as the 
mathematical expression  used to describe relative recovery:
53
  
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 1 − 𝑒𝑥𝑝
(
1
𝑄𝑑(𝑅𝑑+𝑅𝑚+𝑅𝑒)
)
 (1.2) 
where Q
d
 is the flow rate of the perfusate, R
d
, R
m
, and R
e
 are the resistances of the 
dialysate, cellulose membrane, and extracellular matrix space, respectively. The 
resistance of the cellulose membrane is dependent on probe dimensions, including 
sampling region, the molecular weight cut-off of the membrane, and the diffusion 
coefficient of the analytes of interest. 𝑅𝑑 and 𝑅𝑚 account for the diffusion of the analytes 
in the dialysate and membrane, respectively, while 𝑅𝑒 takes into consideration the 
diffusion rate of analytes in the extracellular space.
53-56
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Relative recovery of analytes depends on many factors including flow rate, 
diffusion coefficient of the analyte across the membrane; length and diameter of the 
membrane, diffusion coefficient of analyte within the dialysis membrane; and chemical 
interactions between the analytes and the membrane.
45,57,58
 The length and diameter of 
the membrane can affect a probe’s relative recovery since probes with larger sampling 
regions have more area for the analytes to diffuse through, which increases the recovery 
of analytes.
59-61
 
Relative recovery of microdialysis probes must be determined to obtain 
quantitative analyte information. To do so in vitro, the probe can be calibrated by 
immersing the probe in solutions of known concentrations, obtaining the signal, and 
subsequently creating a calibration curve. This would be compared with the signals that 
are obtained through direct injection of the same concentration of analytes into an 
analysis system, without using microdialysis.
47,62,63
 However, this in vitro calibration 
method may not be representative of the recovery actually attained in vivo, so using in 
vivo calibration methods may be necessary to accurately describe probe recovery.
64-66
 In 
vivo probe recoveries are typically lower than those obtained in vitro. This is most likely 
due to the complexity of the tissue and extracellular matrix, which includes fewer direct 
paths to the microdialysis probe as well as release and uptake of molecules during the 
sampling period.
67 
In order to more accurately calibrate probes in vivo, several methods have been 
developed, including: variation of perfusion flow rates
66
 (“zero flow”),68 no-net-flux,69 
and retrodialysis.
37, 38
 The no-net-flux method is the most commonly used calibration 
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method used in vivo.
60,70
 These experiments take a long time to perform because the 
probe is perfused with different concentrations of the analyte of interest, until there is no 
change in concentration of the analyte between the perfusate and dialysate. To determine 
the relative recovery, the change in dialysate concentration is plotted versus the initial 
perfusate concentration, and the slope of the line is the relative recovery, while the x-
intercept is the extracellular concentration of the analyte of interest.
60
 Because the no-net-
flux experiments take so long to conduct, a retrodialysis method can be used instead. This 
is a delivery experiment where an analyte that is of no interest is added to the perfusate. 
This analyte should have similar properties to the analyte of interest in order to get 
accurate recovery data.
60
 The perfusate with this molecule is then flushed through the 
microdialysis probe and concentration of the dialysate is measured.   
Other factors limiting the capabilities of microdialysis are the temporal and spatial 
resolutions that can be attained. The spatial resolution is determined by the size of the 
sampling region on the probe (1-5 mm typically, in vivo). Probes are oftentimes operated 
at slightly higher flow rates to increase absolute recovery. This is leads to depletion of 
compounds in areas directly around the probe at a more rapid rate, inducing a 
concentration gradient that can extend for several millimeters away from the probe, 
decreasing the spatial resolution.
65
 Spatial resolution is a serious factor in vivo, because 
of damage to surrounding tissue upon implantation of the probe. 
Temporal resolution is defined as the time it takes an analytical system to respond 
to step changes in in analyte concentrations. Temporal resolution affects both in vivo and 
in vitro studies, as well as online and offline coupling of microdialysis to an analytical 
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system. Overall, the temporal resolution that can be attained is affected by factors related 
to capabilities of the analytical system being used, as well as flow rates through the 
microdialysis probe.
46
 Using slower flow rates increases relative recovery, however, 
slows down the rate at which sufficient sample volume can be collected, thus decreasing 
temporal resolution. If biological processes are slower than the sampling and analysis 
time, it is possible to detect changes in abundance as a function of time; however, it may 
not accurately represent dynamics of the system. When this is the case, the temporal 
resolution is defined as the time required for the signal to increase from 10-90% of the 
maximum signal intensity.
70
 
 Microdialysis Coupled to Analytical Systems 1.2.3
In order to couple microdialysis to the analytical system, offline samples can be 
collected or the probe can be directly coupled to the system for online analysis. Despite 
many of the limitations mentioned previously, microdialysis is widely utilized to as a 
sampling method and has been coupled online to CE, LC, and MS, along with other 
analytical methods.
54
  
CE is an analytical separation method that separates molecules based on their 
mobility in an electric field. The mobility of a molecule is determined by a molecule’s 
charge to size ratio.
71
 Jorgenson et al. were the first group to report using CE for 
analytical separations.
72
 In their work, they used glass capillaries that were 80-100 cm in 
length and were moved manually from buffer to sample containing reservoirs. 
Separations of fluorescently labeled amino acids, amines, and dipeptides were 
accomplished in 10-30 min. Since that paper, there have been many advances in the field 
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of CE in order to automate sample injection, improve temporal resolution, and decrease 
separation time.  
Hogan and Lunte were the first to report direct, online coupling of CE to 
microdialysis.
47
 This report was the first to show how coupling microdialysis to CE can 
improve temporal resolution and used an interface that created samples from a continuous 
sampling method. In order to accomplish 
this, Hogan et al. designed an interface on 
a microscope slide. They aligned the 
separation and reaction transfer capillaries 
in a reservoir containing the run buffer. 
This set-up allowed for discrete samples 
to be injected into the separation 
capillary, allowing for online analysis. 
Temporal resolution of 90 s was achieved 
for measuring the pharmacokinetics of 3-
amino-1,2,4-benzotriazine 1,4-di-N-oxide 
in vivo.
47
 
In order to further improve temporal resolution, Jorgenson and Hooker designed a 
transparent flow gate in 1997, as depicted Figure 1.5, for use as a routine and 
reproducible interface between micro-HPLC and capillary zone electrophoresis (CZE).
73
 
The transparent design allowed for alignment of capillaries in the polycarbonate block. 
The flow gate holds the reaction (A) and separation capillaries (B), with an 
Figure 1.5. Flow gate interface developed by 
Jorgenson. Dialysate from the microdialysis 
probe enters through capillary A, which is 
the reaction capillary, B is the separation 
capillary, C is the inlet of buffer flow, and D 
is the outlet that goes to waste. 
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approximately 50 μm gap between them. Separation buffer flows across this gap. During 
a separation, the separation buffer flows through the flow gate and carries any sample 
from the reaction capillary to waste. To perform an injection, flow across the flow gate is 
stopped by a pneumatically actuated valve, and a sample plug fills the gap between the 
capillaries. An injection voltage is applied, which draws the sample plug into the 
separation capillary. After the injection is completed, flow of the separation buffer across 
the flow gate resumes, and a separation voltage is applied.  
This design allowed for coupling of microdialysis with high-speed analytical 
methods, and its usefulness has been demonstrated in various applications.
46,74-76
 The 
flow gate interface allows for discrete sample plugs to be injected into the separation 
capillary for CE separation.
47,73
 Using this set-up, fast separations (~30 s) with high 
temporal resolution can be achieved, even with low flow rates during microdialysis.
73
 
CE is an ideal separation technique to couple with microdialysis because it is 
especially powerful when analyzing biological samples, which typically have very small 
sample volumes. Online CE coupled to microdialysis can provide great temporal 
resolution of analytes in samples because smaller volumes used for separations allow for 
slower flow rates to be used during the sampling.
77,78
 Temporal resolution is also 
improved when microdialysis is coupled to CE because rather than the resolution of 
analytes being dependent on the injection volume and flow rate of perfusate, it is 
dependent on analysis time.
47,54,79
  
Lada and Kennedy were able to improve temporal resolution (from 3 min to 45 s), 
while still achieving high recovery of a number of analytes. The improved temporal 
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resolution was accomplished by coupling microdialysis to CE with laser induced 
fluorescence detection and online derivatization. The flow rate used during these 
experiments was 79 nL/min, compared to a typical flow rate 0.1-1 µL/min, of which 
allowed for higher relative recoveries than had been attained previously.
80
  
 Detection of analytes  1.2.4
Small concentrations of analytes are often collected when sampling a biological 
matrix using microdialysis because only a fraction of analyte is collected. Because 
concentrations are so small, a sensitive detection platform needs to be incorporated into 
the analysis scheme.
81
 Laser induced fluorescence (LIF) is used for the detection of 
fluorescent molecules. LIF works by exciting a molecule to a higher energy state using 
laser light. This causes the spontaneous emission of light, which is detected by a photo 
multiplier tube (PMT) or other detector. LIF is a very sensitive detection method and is 
therefore useful when trying to detect small amounts of analytes.
82
 Previously, Chen and 
Dovichi were able to detect 50 yoctomoles of rhodamine 6G, using LIF detection, 
showing the sensitivity of the technique.
83
  
Molecules oftentimes need to be derivatized with a fluorescent tag because they 
are not natively fluorescent. Many fluorescent tags have been developed for the detection 
of amino acids and other small molecules, including 2,4-dinitrophenyl (DNP), 
napthalene-2,3-dicarboxyaldehyde (NDA), o-phthaldialdehyde (OPA), and FITC.
84-86
 
The fluorescent labels each selectively bond to a moiety on the analytes of interest. This 
allows for the detection and analysis of a particular class of analytes, while eliminating 
interference from unwanted signals. Reducing these interferences improves efficiencies, 
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gives higher plate counts, and lower limits of detection.
87
 The limit of detection is defined 
as the smallest amount of analyte that produces a signal significantly different than a 
blank solution. That value corresponds to three times the standard deviation of the 
baseline signal.
87
 
OPA, and NDA, are compatible for use with microdialysis-CE because they react 
readily at room temperature, under basic aqueous conditions, within 1 minute.
88
 At one 
time, OPA was the most commonly used labeling reagent for microdialysis-CE assays, 
however, OPA labeling is unstable and photobleaching occurs readily.
85
 OPA requires a 
special UV laser due to its absorption in the UV spectrum as well as special optics. In 
addition, it also has poor limits of detection compared to other reagents.
89
 4-Fluoro-7-
Nitro-2,1,3-Benzoxadiazole (NBD-F) was used by early Bowser group members as an 
alternative to OPA derivatization for detection of neuroamines using microdialysis-CE 
(Figure 1.6). NBD-F reacts efficiently with primary and secondary amines and has an 
optimum excitation wavelength of ~ 470 nM, compatible with common 488 nM lasers. 
Figure 1.6. NBD-F labeling reaction. NBD-F (A) reacts with primary and secondary 
amines (B) to produce fluorescently tagged analytes(C) are detected using LIF at 488 nM 
excitation. A by-product (D) is produced by the hydrolysis of NBD-F.  
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Optimization of the derivatization conditions has been previously reported for use in 
assays using microdialysis-CE.
90
 
Although this method has proven successful for derivatization of amines, it is not 
without its drawbacks. One major disadvantage to this derivatization method is the 
reaction by-product that is produced. The reaction by-
product produces a large peak in the middle of the 
electropherograms and without optimization of the 
separation, may obscure analyte peaks. Experimentally, 
the derivatization step in our experimental set-up occurs 
when the dialysate is allowed to react with an NBD-F 
solution in a reaction tee prior to the flow gated 
interface. This derivatized sample then flows in a 
heated reaction capillary to push the reaction to 
completion and passes through the flow gate interface 
for injection into the separation capillary and detection 
in the sheath flow cuvette.
90
 
As a way to improve sensitivity, sheath flow 
cuvettes can be used (Figure 1.7). The sheath flow 
cuvette houses the exit of the separation capillary and sheath flow buffer flows through 
the cuvette and around the capillary. Sheath flow cuvettes are designed based on cuvettes 
used in flow cytometry.
91
 Typical dimensions of cuvettes are 2 mm square with a 400 µm 
× 400 µm square inner bore. The cuvette is made from fused silica and the buffer flowing 
Figure 1.7. Sheath flow 
cuvette used to improve 
sensitivity of LIF detection. 
Fluorescent (native or 
derivatized) sample flows 
through the separation capillary 
(A) and into the sheath flow 
cuvette (B). Sheath flow buffer 
flows around the capillary, 
through the cuvette. A laser 
line (C) is focused just past the 
exit of the capillary exciting 
the sample. 
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through the cuvette matches the refractive index so that the sample is hydrodynamically 
focused as it exits the separation capillary.
92
 It is important that flow out of the separation 
capillary and through the sheath flow cuvette maintain a laminar profile so that detection 
can be performed just past the tip of the separation capillary. The fluorescently labeled 
sample is excited with a laser line and is collected through a microscope objective, passed 
through a series of filters, and is then focused onto a PMT. Using a sheath flow cuvette 
reduces light scattering that normally occurs with on-capillary detection. This advantage, 
plus the optical set-up which uses a pinhole filter, which eliminates background signal, 
allows for very low detection limits
92,93
. Using this technique, Chen and Dovichi were 
able to analyze picomolar solutions, corresponding to attomoles injected, of amino 
acids.
86,93
 Amino acids were labeled using FITC (fluorescein isothiocyanate) and were 
then injected into the CE system. Mass detection of arginine was 9 x 10
−21
 moles.
93
 This 
detection limit shows the power of using the sheath flow detection system because it 
allows for the detection of small analyte concentrations found in biological samples. 
 Biological applications of Microdialysis 1.2.5
Microdialysis is one of the most commonly used sampling methods for in vivo 
analysis and has been used for monitoring small molecule flux in the brain for decades.
94-
101
 Recently, microdialysis has been more broadly used to study other tissues, including 
adipose, liver,
102
 heart,
103
 stomach,
104
 and ears.
105
 Microdialysis experiments allow for 
the study of pharmacokinetics, metabolism,
96-98
 toxicology,
106,107
 and drug delivery,
99-101
 
in various tissues because of the intrinsic small sampling size and quick sampling rate.  
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Typically, microdialysis is coupled to fraction collection, followed by offline 
analysis, giving temporal resolutions of 10 – 30 min.46,47,108 When microdialysis is 
directly coupled to an analytical system, these temporal resolutions can be dramatically 
improved.
46
 When coupled to an online analysis method, the temporal resolution is only 
limited by analytical separation speed, sample volume requirements, and the limits of 
detection for the system. Coupling microdialysis to capillary electrophoresis (CE) is ideal 
due to the small volumes required for CE separation and analysis. 5-10 second sampling 
rates paired with 10-30 second temporal resolution has been achieved after coupling 
microdialysis to a CE system.
74,109,110
 The ability to monitor analytes on this timescale is 
something that very few instrumental set-ups can achieve and the near real-time analysis 
of low concentration analytes makes this instrumental combination ideal for in vivo 
studies.  
CE is one of only a few analytical systems able to monitor 20+ analytes on a 30 
second time scale. This type of temporal resolution allows for in vivo events to be 
monitored at near real-time. Furthermore, chemical release events, such as a response to a 
stimulus, can be easily performed and monitored using microdialysis. Although 
microdialysis has had such success for in vivo studies, in vitro applications have not been 
utilized to their full extent. Previously, microdialysis has been used with cell 
suspensions
111
 or with tissue slices,
112-114
 however, dilution of analytes was problematic 
and results in temporal resolutions of 10-20 min.
16,17,20
 More recently, Hogerton and 
Bowser, successfully cultured C8-D1A astrocytic cell clones on the surface of 
microdialysis probes in order to eliminate the need for fraction collection and improving 
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temporal resolution.
115
 This allowed for near real-time analysis of the cellular response to 
potassium stimulations, while simplifying a full, in vivo model to a cellular model. 
 Scope of Thesis 1.3
Obesity has become a worldwide epidemic and little is understood about the 
development of the disorder. It is understood that adipose tissue regulates whole body 
BCAA levels. Dysregulation of this process has been linked to the development of 
obesity. BCAAs are also known to be important signaling molecules, involved in many 
energy related biological processes. In order to understand what biological factors 
influence the development of obesity, a high throughput MD-CE assay was developed. 
Development of this assay allows for the collection of large amounts of experimental 
data. This is highly important so that we can push the knowledge barrier in biological 
systems, such as 3T3-L1 adipocytes and other obesity models, where basic knowledge is 
lacking.  
In this work, we describe a novel separation assay, capable of monitoring 25+ 
amines, many of which were previously unable to be separated. Chapter 2 describes the 
optimization of this high-speed CE separation assay for analysis of BCAAs released from 
3T3-L1 cells. Optimization of all separation conditions allows for the detection of 
changes in BCAA release in adipocytes, as well as downstream lipogenesis metabolites, 
over various lengths of time. These experiments proved to be useful not only as a proof 
of concept, but provided temporal information about the cellular processes we were 
interested in, namely lipogenesis.  
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Once this temporal information was established, further experiments were 
performed to investigate how local concentrations of BCAAs affect lipogenesis as the 
cells mature from a pre-adipocyte state to fully differentiated adipocytes. This 
information is presented in Chapter 3.  
Investigation of how local glucose concentrations affect lipogenesis at various cell 
differentiation stages was investigated in Chapter 4. This allows us to see the influence 
that each energy substrate (glucose or BCAAs) has on 3T3-L1 adipocytes throughout 
differentiation. Cellular preference toward one particular energy substrate may indicate or 
give insight about other cellular processes the cells are undergoing as they mature into 
full adipocytes.  
Chapter 5 presents preliminary work into the investigation of how insulin affects 
lipogenesis in 3T3-L1 adipocytes. Additionally, preliminary work investigating the 
influence of various sweeteners found in our everyday diets is presented. 
Chapter 6 provides a summary of the work and presents opportunities for future 
directions using the developed technology.  
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 Chapter 2: High-Speed Microdialysis - Capillary Electrophoresis 
Assays for Measuring Branched Chain Amino Acid Uptake in 3T3-L1 
cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with permission from Harstad, R., Bowser, M.T. Anal. Chem., 2016, 88, 8115–
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 Summary 2.1
We have developed a high-throughput microdialysis-capillary electrophoresis (MD-
CE) assay for monitoring branched chain amino acid (BCAA) uptake/release dynamics in 
3T3-L1 cells. BCAAs (i.e., isoleucine, leucine, and valine) and their downstream 
metabolites (i.e., alanine, glutamine, and glutamate) are important indicators of adipocyte 
lipogenesis. To perform an analysis, amino acids were sampled using microdialysis, 
fluorescently labeled in an online reaction, separated using CE, and detected using laser 
induced fluorescence (LIF) in a sheath flow cuvette. Separation conditions were 
optimized for the resolution of the BCAAs isoleucine, leucine, and valine, as well as 13 
other amino acids including ornithine, alanine, glutamine, and glutamate.  CE separations 
were performed in <30 s and the temporal resolution of the online MD-CE assay was <60 
s. Limits of detection (LOD) were 400, 200, and 100 nM for isoleucine, leucine, and 
valine, respectively. MD-CE dramatically improved throughput in comparison to 
traditional offline CE methods, allowing 8 replicates of 15 samples (i.e., 120 analyses) to 
be assayed in <120 min. The MD-CE assay was used to assess the metabolism dynamics 
of 3T3-L1 cells over time, confirming the utility of the assay.   
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 Introduction  2.2
Adipocytes are usually considered as merely storage depots for triglycerides. 
Recent discoveries have changed this thinking demonstrating that adipose tissue 
participates as an endocrine organ, actively modulating chemical messengers involved in 
energy regulation, appetite and inflammation.
4-9
 Amino acids act as primary, small 
molecule messengers in adipose tissue, much like hormones in the endocrine system.
14-
16,116,117
 Of particular interest are the 
branched chain amino acids (BCAAs): 
isoleucine, leucine, and valine. These 
BCAAs are essential amino acids and not 
easily metabolized by the liver.
24
 As such, 
their circulating concentrations rise 
significantly after a high protein meal, 
signaling that energy is abundant and 
stimulating growth. BCAA receptors are 
widespread throughout the body and 
regulate many energy related functions including insulin secretion in the pancreas, 
protein synthesis in muscle, and appetite control in the brain.
14-16
 The heart and kidney 
are also known to metabolize BCAAs.
118,119
  The BCAAs are necessary precursors for the 
TCA cycle and adipocytes therefore must uptake isoleucine, leucine, and valine to 
support lipogenesis.
24,116,117
  Recent evidence suggests that adipocytes regulate circulating 
BCAA concentrations through this uptake, relaying a message to the rest of the body 
Figure 2.1. Brightfield image of fully 
differentiated 3T3-L1 cells. Cells show 
lipid accumulation, confirming successful 
differentiation. 
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regarding the state of energy balance in adipose tissue.
26-29
 Measuring BCAA uptake 
therefore provides information regarding both the internal metabolic activity of 
adipocytes as well as the message they are sending to other tissues involved in energy 
regulation.  The dysregulation of BCAAs has been correlated to obesity, diabetes, and a 
range of other metabolic disorders.
6,7,116,117,120
 
A number of methods have been developed for the analysis of BCAAs. Yang et 
al. developed a two minute LC/MS/MS assay for measuring amino acids in serum.
121
 
Limits of quantitation were 0.7, 2.6, and 0.3 µM for isoleucine, leucine, and valine, 
respectively. GC/MS was used by Perez-Cornago for the analysis of amino acids in 
human serum, with analysis times well over one h per sample.
122
 Other methods for the 
analysis of BCAAs include GC,
123-125
 LC,
27,125,126
 as well as CE with various detection 
methods.
127-129
 Many of these methods require expensive instrumentation, complicated 
sample preparation or offline derivatization steps. A simple, high-throughput assay for 
BCAAs would be beneficial. 
Microdialysis is a common technique for sampling small molecules from 
biological tissues.
54
  A microdialysis probe consists of a short length of hollow fiber, 
semi-permeable membrane connected to two capillary lines in a side-by-side, loop or 
linear arrangement.
45
  Small molecule analytes are able to cross the membrane entering 
the dialysate while larger molecules and cell fragments are excluded.
46
  Typically, the 
probe is implanted into the tissue of interest and perfused with an electrolyte that mimics 
the extracellular fluid. Dialysate is collected in fractions and analyzed offline allowing 
changes in analyte concentrations to be monitored over time. Low perfusion rates and 
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minimum fraction volumes typically yield temporal resolutions of 10-30 min in offline 
MD assays.
46-48,76,108
  The Lunte and Kennedy groups demonstrated that coupling MD 
with an online reaction and high-speed CE analysis dramatically improves temporal 
resolution.
46-48,76
  Temporal resolutions as low as 3 sec have been reported for amine 
neurotransmitters.
74
  MD-CE assays have been developed for a range of amines including 
glutamate, aspartate, GABA, glycine, taurine, glutamine, D-serine and many 
others.
78,79,90,130-132
  To the best of our knowledge no previous MD-CE assay has been 
reported that is able to resolve the BCAA’s.  Online MD-CE assays have largely been 
applied to in vivo measurements.
78,131
  Our group has demonstrated examples of ex vivo 
(salamander retina and mouse cortical slices)
133,134
 and in vitro (C8-D1A astrocytes)
115
 
applications.  We have also demonstrated that online MD-CE can be used as a high 
throughput approach for the analysis of D-serine in tissue homogenates.
130
  In this case, 
the MD probe acts as an efficient mechanism for introducing a series of samples to the 
high-speed CE for analysis. 
In the current manuscript, we describe the development of an online, high-
throughput, MD-CE assay for BCAAs and their downstream metabolites.  The CE 
separation resolves isoleucine, leucine, valine, alanine, glutamine, glutamate and 10 other 
amino acids in <30 sec.  BCAA uptake and amino acid release was measured in 3T3-L1 
cell cultures to demonstrate the utility of the MD-CE assay. 
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 Materials and Methods 2.3
 Chemicals and Reagents  2.3.1
Dulbecco’s Modified Eagle’s Medium (DMEM), newborn calf serum (NCS), 
fetal bovine serum (FBS), and penicillin-streptomycin (5,000U/mL) were purchased from 
Invitrogen Molecular Probes (Eugene, OR). Trypsin solution (0.25% Trypsin/0.53mM 
EDTA in Hank’s Balanced Salt Solution) was purchased from ATCC (Manassas, VA). 
Phosphate-buffered saline (PBS, 10×) was purchased from Bio-Rad Laboratories 
(Hercules, CA). Ciglitazone was purchased from VWR International (Radnor, 
Pennsylvania). α-Cyclodextrin was purchased from CTD Holdings, Inc. (technical grade, 
Alachua, FL). 3-Isobutyl-1-methylxanthine (IBMX), dexamethasone, insulin (human), 
and all amino acids were purchased from Sigma-Aldrich (St. Louis, MO). Mammalian 
Protein Extraction Reagent (M-PER®), Halt Protease Inhibitor Cocktail, EDTA free, 
Halt™ Phosphatase Inhibitor Cocktail, and sodium borate tetrahydrate were purchased 
from Fisher Scientific (Pittsburgh, PA).  
 Buffers and Solutions 2.3.2
All solutions were prepared in deionized water (Milli-Q, 18.2 MΩ; Millipore, 
Bedford, MA) and filtered (0.22µm) unless otherwise noted. Sheath flow buffer 
contained 90 mM borate adjusted to pH 9.8. CE separation buffer contained 90 mM 
borate/35 mM α-cyclodextrin adjusted to pH 9.8. Ringer’s solution was prepared with 
123 mM NaCl, 1.5 mM CaCl2, and 5 mM KCl, adjusted to pH 7.5; and then autoclaved 
for sterilization. Derivatization solution was prepared daily by dissolving 4-fluoro-7-
nitrobenzofurazan (NBD-F, TCI America, Portland, OR) in methanol and diluting with 
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equal parts 500 µM HCl and degassing under vacuum, giving a final solution of 20 mM 
NBD-F/250 µM HCl in 1:1 methanol:water. Stock standard solutions (1 mM) of amino 
acids were prepared in Ringer’s solution. 
 Offline Optimamization of CE Separation Conditions 2.3.3
Optimization of CE separation conditions was performed using a P/ACE MDQ 
system  equipped with a LIF detector (λex = 488 nm; λem = 520 nm) and a 3 mW argon 
ion laser (Beckman Coulter, Fullerton, CA).  A 50 µm i.d. × 40 cm fused silica capillary 
(Polymicro Technologies, Phoenix, AZ) was used for CE separations.  On column LIF 
detection was performed 30 cm from the inlet.  Each day, the capillary was rinsed with 
0.1 M NaOH, water, and CE separation buffer for 5 min each at 20 psi before the first 
separation.  Between separations, the capillary was rinsed with 0.1 M NaOH for 1 min 
(20 psi), followed by 2 min of water and 2 min of separation buffer (20 psi).  Amines 
were fluorescently labeled in an offline reaction by mixing 5 mM NBD-F dissolved in 
350 µL MeOH with 350 µL of amino acid standard prepared in Ringer's solution and 300 
µL CE separation buffer. The solution was mixed and heated in a water bath at 80 ºC for 
5 min.  NBD labeled amine standards (20 µM) were injected onto the CE capillary for 10 
sec at 0.5 psi and separated using 21 kV (normal polarity) for 10 min 
 Cell Culture 2.3.4
3T3-L1 fibroblasts (ATCC® CL-173™) were cultured in 25 cm2 tissue culture 
flasks (T-25 flasks) containing 8 mL of high glucose DMEM supplemented with 10% 
NCS and 1% penicillin/streptomycin. Cultures were kept in a 37° C incubator (5% CO2) 
and were passaged every 3-4 days using a ratio of 1:8, with 0.25% (w/v) Trypsin/0.53 
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mM EDTA solution. Once a confluent monolayer was established, 3T3-L1 cells were 
differentiated into mature adipocytes using previously described methods.
44
 Briefly, 
differentiation was induced by adding DMEM containing 10% FBS, 0.5 mM IBMX, 0.25 
µM dexamethasone, 2µM ciglitazone, and 170 µM insulin. The IBMX, ciglitazone, and 
dexamethasone were removed after 48 h, and the insulin was removed after 96 h. 
Experiments were conducted at this time point (96 h after differentiation induction). 
Successful differentiation cannot be confirmed visually until lipids have accumulated. 
We therefore continued the process past the 96 h point to confirm successful 
differentiation visually by the accumulation of lipid droplets (see Figure 2.1). 
 In vitro Microdialysis 2.3.5
Side-by-side microdialysis probes were constructed in-house, as described 
previously.
131
 Two 40 µm i.d. × 105 µm o.d. fused silica capillaries (Polymicro 
Technologies, Phoenix, AZ) were inserted into a 200 µm i.d. piece of hollow fiber, 
regenerated cellulose, dialysis tubing (13 kD MWCO, Spectrum Laboratories, Inc., 
Rancho Dominguez, CA). The capillaries were offset by 1 cm to create a sampling region 
and sealed using polyimide resin (Alltech, Deerfield, IL). Probes were conditioned by 
flushing with ethanol (45 µL/h) for 5 min, followed by 10 min of Ringer’s solution (25 
µL/h). During analysis, probes were perfused with Ringer’s solution at 25 µL/h. 
 Online Derivatization  2.3.6
Dialysate was carried in a 30-40 cm long × 40 µm i.d. × 360 µm o.d. fused silica 
capillary (Polymicro Technologies, Phoenix, AZ) to a 250 µm i.d. stainless steel cross 
(Valco Instruments Co. Inc., Houston, TX) where it was mixed with a 5 µL/h stream of 
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borate buffer and a 5 µL/h stream of NBD-F derivatization solution (see Figure 2.2).  
Amino acid derivatization took place as the dialysate traveled through a 90 cm long, 75 
µm i.d. × 360 µm o.d., fused silica capillary from the reaction cross to the flow gate 
interface. A 66 cm portion of the reaction capillary was heated to 80°C to accelerate the 
reaction by passing the capillary through flexible tubing that circulated water from a 
water bath (NESLAB EX-7 Digital One heating bath circulator, Thermo, Newington, 
NH).
90
 The length of the reaction capillary and flow rates used resulted in a 5 min 
reaction time.
90
 
 High-Speed Capillary Electrophoresis 2.3.7
A flow gate interface
73
 was used to inject discrete plugs of labeled dialysate into 
an 8–8.5 cm long, 10 µm i.d. × 360 µm o.d. fused silica CE separation capillary 
(Polymicro Technologies, Phoenix, AZ). The reaction and separation capillary were 
aligned coaxially in a polycarbonate flow gate interface block with a gap of ~50 µm. 
Separation buffer flowing at 40 mL/h was pumped through this gap using a syringe pump 
(Pump 22 syringe pump, Harvard Apparatus, Holliston, MA). To perform an injection, a 
pneumatically actuated valve (C2-300A 10 port valve, Valco Instruments Co. Inc., 
Houston, TX) was used to stop the cross flow for 500 ms allowing the gap between the 
derivatization and separation capillaries to fill. An injection voltage of -13 kV was 
applied to the exit of the separation capillary for 200 ms. The cross flow though the flow 
gate was resumed and a separation voltage of -19 kV was applied at the outlet of the 
separation capillary. Injections were controlled using an in-house LabVIEW program. CE 
separations were performed every 30 sec. 
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 LIF Detection 2.3.8
LIF detection was performed at the exit of the CE separation capillary in a fused-
silica sheath flow cuvette (2 mm square with a 400 µm × 400 µm square inner bore).
82,135
  
The 488 nm line of an argon ion laser (150 mW, Melles Griot, Carlsbad, CA) was passed 
through a 10× beam expander (Edmond Optics, Barrington, NJ), and focused using a 1× 
lens to a point just below the exit of the CE separation capillary in the sheath flow 
cuvette. Fluorescence emission was collected at 90° with a 60×, 0.7 NA long working 
Figure 2.2. Schematic of the online MD-CE system. The microdialysis probe is placed 
into a microcentrifuge tube containing the amino acids sample. Ringer’s solution is 
perfused through the microdialysis probe, where small molecules diffuse across the 
membrane and are carried to the reaction cross. Primary and secondary amines are 
fluorescently labeled using NBD-F as they travel through the reaction capillary to the 
flow gate interface for injection. Labeled amines are injected, separated using CE, and 
detected using LIF in a sheath flow cuvette every ~30 seconds. 
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distance objective (Universe Kogaku, Oyster Bay, NJ), filtered through spatial (~1 mm 
diameter) and bandpass filters (543.5 ± 10 nm) (Melles Griot, Irvine, CA) and measured 
using a photomultiplier tube (PMT, R1477, Hamamatsu Corp., Bridgewater, NJ). Current 
from the PMT was converted to a potential (Keithley 428 Current Amplifier, Keithley 
Instruments Inc., Cleveland, OH), filtered with a 10 ms rise time, and recorded using a 
data acquisition card (National Instruments Corp., Austin, TX). Data analysis was 
performed using Cutter Analysis 7.0.
136
 
 Measuring BCAA Uptake 2.3.9
3T3-L1 cells were cultured and maintained in T25 flasks as described above until 
a confluent monolayer was established. The differentiation process proceeded for 96 h. 
Cells were washed four times with 1.00 mL Ringer’s solution containing 200 µM of 
isoleucine, leucine, and valine and 5 mM glucose (incubation medium). After four 
washes, 1.00 mL of incubation medium was added to the flask. Flasks were placed in the 
incubator and allowed to incubate for various lengths of time (5, 15, 30, 45 or 60 min). 
After the incubation period, 500 µL was withdrawn from the flask, spiked with 25 µL of 
1 mM D-2-amino-adipic acid, which is used as an internal standard, and used for CE 
analysis. To remove the 3T3-L1 cells from the flask for protein analysis, 1.00 mL of 
mammalian protein extraction reagent supplemented with Halt Protease Inhibitor 
Cocktail, EDTA free, and Halt™ Phosphatase Inhibitor Cocktail was added to the flask 
and allowed to incubate at room temperature for 5-30 min until all cells were detached 
from flask walls. This 1.00 mL aliquot was collected for protein quantification using a 
bicinchoninic acid (BCA) assay. 
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 Bicinchoninic Acid (BCA) Assay  2.3.10
All measured amino acid concentrations were normalized according to cell protein 
content using a BCA assay. In order to measure cell protein content, a Pierce™ BCA 
Protein Assay Kit was purchased and utilized according to included instructions. Briefly, 
working reagent was prepared by combining “Reagent A” and “Reagent B” in a ratio of 
50:1 (A: B). 25 µL of each sample or standard was pipetted into individual wells of a 96 
well plate; 200 µL of working reagent was then added to each well. All samples were 
measured in triplicate. The plate was gently shaken for 30 s to ensure mixing of the 
working reagent and samples. The plate was then incubated at 37°C for 30 min. The plate 
was removed from the incubator and the absorbance at 562 nm was recorded using a 
plate reader (Spectromax Plus; Molecular Devices). A calibration curve was generated 
from standards. Using this standard curve, protein content from each flask was 
determined and used for normalizing amino acid signals obtained from CE separation.  
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 Results and Discussion 2.4
 CE Separation 2.4.1
Optimization  
Previous studies have 
demonstrated online MD-CE 
assays able to separate and detect 
20 biological amines in 20 
sec.
90,115
  These studies were 
optimized for the analysis of 
neurochemicals including 
glutamate, aspartate, GABA, 
glycine, and taurine  Notably, the 
BCAAs are not resolved under 
these conditions (see Figure 2.3A).  
Isoleucine and leucine are 
particularly difficult to separate 
under physiological conditions due 
to their identical molecular 
weights and similar chemical 
structures. We initially made 
minor changes to our previously 
reported MD-CE conditions
90
 in an 
Figure 2.3. Electropherograms from online 
MD—CE analyses of a 20 µM standard amino 
acid solution. (A) Separation Buffer: 100 mM 
borate/20 mM HP-β-CD, pH=10.5; Peaks 
Identified: (1) NBD-OH, (2) leucine, isoleucine, 
(3) valine, (4) citrulline. (B) Separation Buffer, 
90 mM borate/35 mM α-CD, pH=9.8; Peaks 
Identified: (1) PEA, arginine, (2) threonine, (3) 
lysine, (4) isoleucine, (5) leucine, (6) ornithine, 
(7) methionine, (8) phenylalanine, (9) valine, 
citrulline, (10) α-ABA, (11) histidine, (12) 
GABA, (13) glutamine, (14) alanine, (15) β-
ABA, (16) threonine, (17) β-alanine, (18) glycine, 
(19) NBD-OH, (20) taurine, (21) internal 
standard, (22) glutamate, and (23) aspartate.   
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attempt to separate 
isoleucine and leucine 
without losing 
separation of previously 
resolved analytes.  
Unfortunately, we were 
unable to resolve 
isoleucine and leucine 
through modifications 
to the separation buffer 
pH or HP-β-CD 
concentration. Lorenzo 
et al. previously demonstrated near baseline resolution of NBD labeled isoleucine and 
leucine using CE with a borate/β-CD separation buffer.129  Unfortunately, this protocol 
did not provide sufficient resolution under conditions necessary for our online MD-CE 
assay. This forced us to re-evaluate the separation more thoroughly. 
Optimization of the separation was performed using an automated, commercial 
CE system.  Although the separations take longer using the commercial system, 
separation conditions are more easily changed allowing a wide range of separation 
buffers to be assessed efficiently. Our initial strategy was to assess a range of separation 
buffers and complexation additives to determine which had the potential to resolve the 
NBD labeled BCAA’s.  Various aqueous and methanol based buffers were assessed 
Figure 2.4. Effect of buffer additives on CE separation of 
NBD labeled BCAA’s and related metabolites (20 µM).  
Separation Buffer: 90 mM borate at pH = 9.8 with 20 mM 
SDS, 7.5 mM β-CD, 12 mM γ-CD or 2 mM α-CD.  Peak 
Identification:  1) isoleucine, 2) leucine, 3) valine, 4) alanine 
and 5) glutamate. 
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including: 7.5 mM β-CD in 90 mM borate (pH= 10.0), 12 mM α-CD in 90 mM borate 
(pH = 10.0), 12 mM γ-CD in 90 mM borate (pH= 10.0), 10 mM SDS in 100 mM borate 
(pH = 10.5), MeOH with 50 mM borate, MeOH  With Triton X-100/50 mM borate, and 
MeOH with CAPS/50 mM borate.  As shown in Figure 2.4, addition of α-CD and γ-CD 
to the separation buffer provided the most promising leads for the resolution of isoleucine 
and leucine. 
Our next step was to assess 
the separation of the NBD labeled 
BCAA’s across a range of α-CD 
and γ-CD concentrations to 
identify the window of conditions 
where adequate resolution of 
isoleucine and leucine was 
achieved.  As shown in Figure 2.5, 
both α-CD and γ-CD are able to 
partially resolve NBD labeled 
isoleucine and leucine across a 
range of concentrations.  Better 
resolution was observed across a wider range of concentrations using α-CD so this buffer 
additive was used going forward. 
Figure 2.5. Effect of α-CD and γ-CD concentration 
on CE separation of NBD labeled BCAA’s and 
related metabolites (20 µM).  Separation Buffer: 90 
mM borate at pH = 9.8 with 50 γ-CD, 12 mM γ-CD, 
50 mM α-CD or 12 mM α-CD.  Peak Identification:  
1) isoleucine, 2) leucine, 3) valine, 4) alanine and 5) 
glutamate. 
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After the separation window 
of α-CD concentrations was 
identified, it remained necessary to 
find conditions where the NBD 
labeled BCAA’s were resolved from 
other amines commonly encountered 
in biological samples. Figure 2.6 
demonstrates CE separations of a 
mixture of 20 NBD labeled amines 
across a range of α-CD 
concentrations.  Addition of α-CD 
had a pronounced effect on the 
position of the NBD-OH peak in the 
separation.  NBD-OH is a hydrolysis 
byproduct of the fluorogenic labeling 
reaction, which often obscures nearby analyte peaks.  Increased α-CD concentration 
selectively pulls many analytes well ahead of the NBD-OH peak, improving resolution in 
the region of the electropherogram where the peak density is highest.  
From these separations 35 mM α-CD was chosen as the optimum separation 
buffer that balanced resolution of isoleucine/leucine pair with resolution of valine from 
phenylalanine, lysine and α-aminobutyric acid.  α-CD concentrations higher than 35 mM 
increased separation time without further improving resolution.  It should be noted that 
Figure 2.6. Effect of α-CD concentration on CE 
separation of NBD labeled amines (20 µM).  
Separation Buffer: 90 mM borate at pH = 9.8 
with 15-40 mM α-CD.  Peak Identification:  1) 
lysine, 2) isoleucine, 3) leucine, 4) methionine, 5) 
phenylalanine, 6) valine, 7) lysine/α-
aminobutyric acid, 8) histidine, 9) GABA, 10) 
alanine, 11) β-aminobutyric acid, 12) β-alanine, 
13) glycine, 14) NBD-OH, 15) taurine, 16) 
glutamate, 17) aspartate.  
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the peak density of early migrating 
analytes is approaching the peak 
capacity of the separation requiring 
careful control of the separation 
conditions.  Once optimized there is 
little opportunity for further 
adjustments to squeeze out additional 
resolution between individual analyte 
pairs without losing resolution 
elsewhere in the electropherogram.  
Figure 2.3B shows the 
separation of a similar amine mixture 
analyzed using the online MD-CE 
instrument, demonstrating that the 
separation conditions optimized using the commercial instrument are directly transferable 
to our high-speed assay..  Twenty-one amino acids were resolved in <30 sec.  Isoleucine 
and leucine were separated while maintaining resolution from the other amines expected 
to be present.  Alanine, glutamine, and glutamate, all downstream BCAA metabolites and 
potential biomarkers of lipogenesis, were also well resolved.  Unfortunately, valine co-
migrates with citrulline under the newly optimized conditions. We confirmed that no 
measureable citrulline is effluxed from 3T3-L1 cells using the original separation 
conditions shown in Figure 2.3A (see Figure 2.7).  Efficiencies of 216,000 (isoleucine), 
Figure 2.7. Electropherogram from an online 
MD-CE analysis of supernatant and standard 
solutions after 3T3-L1 cells were incubated 
with Ringer’s Solution + 5 mM glucose and 200 
µM isoleucine, leucine, and valine. Separation 
Buffer: 100 mM borate/20 mM HP-β-CD, 
pH=10.5. The cell sample (black) has been 
offset for clarity from individual 20 µM 
standard solutions of valine (red) and citrulline 
(green). Valine and citrulline are clearly 
resolved under these separation conditions. No 
citrulline is observed in the cell supernatant. 
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170,000 (leucine), and 100,000 (valine) 
theoretical plates were observed with 
average peak widths of ~220 ms.  The % 
relative standard deviation (%RSD) of 
peak heights in replicate measurements 
ranged from 23-26% for the BCAA’s.  
Normalization with the internal standard 
improved reproducibility dramatically, 
reducing %RSD in replicate peak height 
measurements to 5-7%.  
 Temporal Resolution and 2.4.2
Limits of Detection (LOD)  
To measure the temporal 
resolution of the MD-CE assay, a microdialysis probe was transferred from Ringer’s 
solution to a 20 µM standard of 24 amino acids for three min and then returned to 
Ringer’s solution. Electropherograms were recorded every 30 s. As shown in Figure 2.8, 
peak height reached a plateau within 2-3 separations, indicating that the MD-CE assay is 
able to respond to changes in concentration at the probe surface with 60-90 second 
temporal resolution.  The temporal response of the assay is limited by diffusion that 
occurs as analytes travel through the connecting capillary from the microdialysis probe to 
the flow gate interface.  The high temporal resolution of the MD-CE instrument allows a 
high-throughput analysis of a series of samples to be performed.  The microdialysis probe 
Figure 2.8. MD-CE analysis for valine as the 
microdialysis probe is moved between 
Ringer’s and amino acid standard solutions of 
increasing concentrations. Electropherograms 
were recorded every 30 s.  Maximum peak 
height is achieved within 2-3 separations, 
demonstrating 60-90 s temporal resolution.  
Inset is an expanded view of the 0.5 µM – 5 
µM analyses. 
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can simply be transferred between a 
sample or standard and Ringer’s 
solution, then back to another sample 
for continuous sampling.  Ten 
replicates can be obtained in as little 
as 5 min (30 s/separation) with only 
1-2 min between samples.  
 A similar analysis using 
offline CE would typically take >100 
min to perform 10 replicate 
separations.  Manual labeling 
reactions for individual samples 
would also be necessary, further 
reducing throughput.  As shown in 
Figure 2.8, concentrations as low as 
500 nM can reliably be analyzed 
using the online MD-CE assay.  
Limits of detection of the assay for 
the BCAAs were estimated to be 400, 
200, and 100 nM for isoleucine, 
leucine, and valine, respectively. 
Figure 2.9. Electropherogram from an online 
MD-CE analysis of supernatant after 3T3-L1 
cells were incubated with Ringer’s solution + 5 
mM glucose and 200 µM isoleucine, leucine and 
valine for 30 min.  A) depicts the full 
electropherogram.  The scale is expanded in B) to 
demonstrate the BCAA separation more clearly. 
Peaks identities are: (1) lysine, (2) isoleucine, (3) 
leucine, (4) ornithine, (5) methionine, (6) 
phenylalanine, (7) valine, (8) ornithine, (9) 
GABA, (10) glutamine, (11) alanine, (12) 
threonine, (13) β-alanine, (14) glycine, (15) 
NBD-OH, (16) taurine, (17) internal standard, 
(18) glutamate, (19) aspartate. 
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These are LODs for the BCAA concentration outside the probe and therefore account for 
microdialysis recovery and labeling efficiency in the online reaction. 
 BCAA Uptake and Amino Acid Efflux and in 3T3-L1 Cells   2.4.3
3T3-L1 cells were grown to confluency in T-25 flasks and differentiation was 
induced. Experiments were performed 96 h into the induction protocol.  This time point 
was chosen because 3T3-L1 cells are 
not yet fully differentiated into 
mature adipocytes and are rapidly 
accumulating lipids through 
lipogenesis.  Cells were incubated 
with 1.00 mL of 5 mM glucose 
containing 200 µM isoleucine, 
leucine, and valine for a set time 
period after which the supernatant 
was removed for MD-CE analysis.  A 
typical electropherogram after 30 min 
of incubation is shown in Figure 2.9.  
Peaks for the BCAAs isoleucine, 
leucine and valine are clearly 
observed.  During the incubation 
period 3T3-L1 cells effluxed many 
biogenic amines not present in the 
Figure 2.10. Butterfly plot of electropherograms 
comparing biogenic amine concentrations in the 
supernatant of 3T3-L1 cells incubated with 
Ringer’s solution + 5 mM glucose and 200 µM 
isoleucine, leucine and valine for 5 min (top) and 
60 min (bottom).  Peak intensities of the BCAAs 
decreased with longer incubation indicating net 
uptake consistent with lipogenesis.  Other 
biogenic amines were effluxed over the 
incubation period.  Peaks identities are: (1) 
lysine, (2) isoleucine, (3) leucine, (4) ornithine, 
(5) methionine, (6) phenylalanine, (7) valine, (8) 
ornithine, (9) GABA, (10) glutamine, (11) 
alanine, (12) threonine, (13) β-alanine, (14) 
glycine, (15) NBD-OH, (16) taurine, (17) internal 
standard, (18) glutamate, (19) aspartate. 
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incubation medium giving rise to clear peaks, well above the LOD.  Effluxed amines that 
were detected include lysine, ornithine, alanine, glutamine, glutamate, taurine, and 
glycine. Peak identities were confirmed by transferring the microdialysis probe from an 
aliquot of the cell supernatant to a vial containing individual amines and then returning to 
the original sample to clearly identify which peaks co-migrated with the standards. 
Figure 2.10 compares 
electropherograms recorded after 
different incubation times.  The 
peak intensities of effluxed biogenic 
amines increased with longer 
incubation periods.  It should be 
noted that the rate of increase varied 
for different amines.  Differing rates 
of release, combined with a gradual 
release over time, confirms that the 
cells did not lyse prematurely and 
that the observed changes in 
concentration are due to a cellular response.  The intensities of the peaks for the 
isoleucine, leucine and valine decreased over time, consistent with the BCAA uptake 
necessary for lipogenesis.  This is an important confirmation that the MD-CE assay is 
able to detect net BCAA uptake into 3T3-L1 cells at the concentrations and incubation 
times assessed.   
Figure 2.11. Net BCAA uptake by 3T3-L1 cells 
incubated with Ringer’s solution + 5 mM glucose 
and 200 µM isoleucine, leucine and valine for 
time periods ranging from 5 to 60 minutes.  Rates 
were normalized to cell protein content as 
determined by BCA assay.  Error bars are SE for 
n=3 samples. 
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Figure 2.11 shows the net rate 
of isoleucine, leucine and valine 
uptake observed over incubation times 
ranging from 5 to 60 min.  Rates were 
normalized to the protein content of 
the 3T3-L1 cells (BCA assay) to 
account for differences in cell number 
or size between incubation flasks.  
The net rate of uptake was highest 
within the first 5 min of incubation 
with sustained uptake occurring over 
periods as long as 60 min.  The high 
initial rate of uptake indicates that 
3T3-L1 cells respond quickly to 
glucose and BCAA exposure.  Assays 
with fast sampling rates will therefore 
be necessary to accurately observe the 
response of 3T3-L1 cells to stimuli 
that induce lipogenesis.  
Figure 2.12 shows the net rate 
of efflux for glutamine, alanine, and 
glutamate over incubation times 
 
Figure 2.12. Net rate of glutamine, alanine and 
glutamate efflux by 3T3-L1 cells incubated with 
Ringer’s solution + 5 mM glucose and 200 µM 
isoleucine, leucine and valine for time periods 
ranging from 5 to 60 minutes. Rates were 
normalized to cell protein content as determined 
by BCA assay. Error bars are SE for n=3 
samples. 
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ranging from 5 to 60 min.  Glutamine, alanine, and glutamate are downstream 
metabolites of lipogenesis.  Increased efflux of these amino acids may therefore be able 
to be used as biomarkers of increased lipogenesis.  The observed trends in glutamine, 
alanine, and glutamate efflux track those observed for BCAA uptake, supporting this 
hypothesis. Again, the rate of efflux is highest within the first 5 min of incubation, 
reinforcing the need for high temporal resolution assays to monitor changes in adipocyte 
metabolism.  
 Conclusions 2.5
We have demonstrated an online MD-CE assay for BCAAs and their downstream 
metabolites.  Separation conditions were optimized to resolve isoleucine, leucine, valine, 
glutamine, alanine, glutamate and many other biogenic amines in <30 sec.  Peak widths 
were ~220 ms with theoretical plates reaching >150,000.  The combination of simple 
microdialysis sample introduction with high-speed CE separation allowed us to perform a 
high-throughput analysis of a series of biological samples.  In this study, we were able to 
analyze 15 samples with 8 replicates/sample in 2 h.  A similar analysis using traditional 
offline CE would have taken >20 h. 
The BCAAs and their downstream metabolites play key roles in the TCA cycle 
and lipogenesis in adipocytes.
30
  Monitoring BCAA uptake and downstream metabolite 
efflux may therefore allow us to gain insight into how adipocyte metabolism responds to 
various stimuli including food ingredients/additives or environmental toxins.  This 
information is sorely lacking in our attempts to better understand what is driving the 
obesity epidemic facing modern society.  The MD-CE assay described here provides a 
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high-throughput assay that can be used to perform these studies in traditional adipocyte 
cell models.  The assay is also compatible with in vivo or in vitro MD-CE approaches, 
which would allow higher temporal resolution studies to be performed in a wider range of 
obesity models. 
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 Chapter 3: Utilization of Branched Chain Amino Acids by 3T3-L1 
Adipocytes throughout Differentiation 
  47 
 Summary 3.1
Net release and uptake of the branched chain amino acids (BCAAs), isoleucine, 
leucine, and valine, as well as the downstream metabolites of lipogenesis, alanine, 
glutamine, and glutamate, was monitored using online microdialysis-capillary 
electrophoresis with laser induced fluorescence detection (CE-LIF). Changes were 
monitored in order to see how utilization of BCAAs changed throughout differentiation 
as lipogenic needs changed. Differences in net release and uptake profiles were observed 
at various stages in the 3T3-L1 differentiation process into mature adipocytes. BCAA 
release is lowest during periods of increased lipogenesis and uptake of BCAAs is highest 
during this same time period. It was also observed that BCAA release and uptake is 
slowed once the cells have reached a fully differentiated state. Downstream metabolites 
supported these trends with increased release during later stages of development when 
lipogenesis occurs most rapidly. The presence of physiological concentrations of BCAAs 
appears to stimulate lipogenesis, as indicated by an increase in downstream lipogenic 
markers.   
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 Introduction  3.2
Branched chain amino acids play an important role in signaling throughout the 
body and evidence suggests that adipocytes regulate BCAA concentrations through 
uptake, providing signals to the rest of the body about the state of energy balance in 
adipose.
26-29,137-139
 BCAA receptors can be found throughout the body, and are known to 
regulate insulin secretion, protein synthesis in muscle, and appetite control in the brain.
14-
16
 After consuming a high protein meal, systemic BCAA levels increase, sending a signal 
that there is a surplus of energy.
6,7,24
 Protein turnover is closely regulated by leucine 
through its ability to stimulate protein synthesis and inhibit protein degradation.
140,141
 
The catabolism of BCAAs in adipose tissue supports lipogenesis and the 
generation of tricarboxylic acid (TCA) cycle intermediates (Figure 1.2).
30,116,117,142-145
 
Green et al. demonstrated that proliferating 3T3-L1 cells use glutamine and glucose in 
order to generate acetyl coenzyme A (CoA) to be used in the TCA cycle in order to 
produce energy for the cells. They also showed that differentiating cells used isoleucine 
and leucine in order to generate nearly 1/3 of acetyl-CoA used in the TCA cycle, rather 
than glucose and glutamine alone.
30
  
Rapid accumulation of lipids occurs in late stages of 3T3-L1 differentiation, 
usually 5-7 days after the initiation of differentiation. Cells use BCAAs in order to 
rapidly produce TCA cycle intermediates for storage of energy as triglycerides. Excess 
energy is stored in adipocytes as triglycerides, for later use when energy stores are low. 
Through lipid accumulation, cells are able to regulate whole body BCAA levels. In order 
to assess how physiological concentrations of BCAAs modulate amino acid release and 
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uptake, we use the immortalized 3T3-L1 mouse model cell line. 3T3-L1 cells were 
isolated from parent 3T3 cultures after identification of colonies with a lipid 
accumulating phenotype once cells reached confluency.
39
 These cells are simple to 
culture compared to primary cell lines and have well established protocol for 
differentiation. Other cell lines commonly used for adipocyte research include 3T3-
F422A, TA1, and OB1771.
17
 Various differentiation procedures were tested until a 
protocol with nearly 100% differentiation was achieved.
40,146,147
 
Microdialysis sampling is used to create a high-throughput sampling method, and 
has been used in combination with CE for the sampling of various biological amines 
including glutamate, aspartate, GABA, glycine, taurine, glutamine, D-serine, and many 
others.
74,78,79,90,130-132
 Using microdialysis sampling coupled with an online reaction and 
high-speed CE has been shown to dramatically improve temporal resolution; temporal 
resolutions as low as 3 s have been achieved for amine neurotransmitters.
74
 We used a 
previously developed high-speed CE separation scheme to measure BCAAs and related 
amines.
148
 This method allows for the detection of BCAAs and the downstream markers 
of lipogenesis, alanine, glutamine, and glutamate, among other amino acids. In total, 22 
amino acids can be separated in less than 30 s using this method. Limits of detection for 
amino acids of interest are as low as 100 nM for valine, 400 nM for isoleucine, and 300 
nM for leucine.
148
  
In this work, we used a high-speed CE-LIF method for the separation, detection, 
and analysis of amino acids released from 3T3-L1 cells. This allows us to study the effect 
of BCAAs on lipogenesis at different stages throughout differentiation. 
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 Materials and Methods 3.3
 Chemicals and Reagents 3.3.1
α-Cyclodextrin was purchased from CTD Holdings, Inc. (technical grade, 
Alachua, FL). 3-Isobutyl-1-methylxanthine (IBMX), dexamethasone, insulin, and all 
amino acids were purchased from Sigma-Aldrich (St. Louis, MO). Dulbecco’s Modified 
Eagle’s Medium (DMEM), newborn calf serum (NCS), fetal bovine serum (FBS), and 
penicillin-streptomycin (5,000U/mL) were purchased from Invitrogen Molecular Probes 
(Eugene, OR). Trypsin solution (.25% Trypsin/0.53mM EDTA in Hank’s Balanced Salt 
Solution) was purchased from ATCC (Manassas, VA). Phosphate-buffered saline (PBS, 
10X) was purchased from Bio-Rad Laboratories (Hercules, CA). Ciglitazone was 
purchased from VWR International (Radnor, Pennsylvania). Mammalian Protein 
Extraction Reagent (M-PER®), Halt Protease Inhibitor Cocktail, EDTA free, Halt™ 
Phosphatase Inhibitor Cocktail, a Pierce™ BCA Protein Assay Kit (product 23225), and 
sodium borate tetrahydrate were purchased from Fisher Scientific (Pittsburgh, PA). 4-
Fluoro-7-Nitro-2, 1, 3-Benzoxadiazole (NBD-F) was purchased from TCI America 
(Portland, OR). 
 Buffers and Solutions  3.3.2
All solutions were prepared in deionized water (Milli-Q, 18.2 MΩ; Millipore, 
Bedford, MA) and filtered (0.22µm) unless otherwise described. CE separation buffer 
contained 90 mM borate/35 mM α-cyclodextrin and was adjusted to pH 9.8. Sheath flow 
buffer contained 90 mM borate and was also adjusted to pH 9.8. Ringer’s solution was 
prepared with NaCl (123 mM), CaCl2 (1.5 mM), and KCl (5 mM), pH 7.5, and then 
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autoclaved for sterilization. Derivatization solution was prepared daily by dissolving 40 
mM NBD-F in methanol and diluting in equal parts with 500 µM HCl, giving a final 
solution of 20 mM NBD-F/250 µM HCl in 50% methanol which was degassed under 
vacuum for 2 min. Stock standard solutions (1 mM) of amino acids were prepared 
individually in Ringer’s solution. 
 Cell Culture 3.3.3
3T3-L1 fibroblasts (ATCC® CL-173™) were maintained in 25 cm2 tissue culture 
flasks (T-25 flasks) containing 8 mL of high glucose DMEM supplemented with 10% 
NCS and 1% penicillin/streptomycin. Cultures were maintained in a 37° C incubator (5% 
CO2). 3T3-L1 cells were differentiated using methods previously described 
146
. Briefly, 
differentiation was induced by adding high glucose DMEM containing 10% FBS, 0.5 
mM IBMX, 0.25 µM dexamethasone, 2 µM ciglitazone, and 170 µM insulin. IBMX, 
ciglitazone, and dexamethasone were removed after 48 h, and insulin was removed after 
4 days. Maintenance media (high glucose DMEM, 10% FBS, and 1% 
penicillin/streptomycin) was used after 4 days. Experiments were conducted at 4 different 
time points—“Day 0” is prior to any differentiation, but confluent; “Day 2” is after 48 h 
of incubation with DMEM, FBS, IBMX, dexamethasone, ciglitazone, and insulin; “Day 
4” is 96 h after differentiation induction, when media contains DMEM, FBS, and insulin; 
and finally, “Day14” is 14-16 days after time point “Day 0.” Images were taken using a 
SPOT Insight QE camera (Model 4.1, Diagnostic Instruments, Inc., SPOT Imaging, 
Sterling Heights, MI) mounted on a LaboMED TCM400 microscope (Labo America Inc., 
Fremont, CA) at 20×. 
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 Measuring Bulk Branched Chain Amino Acid Uptake/Release  3.3.4
3T3-L1 cells were cultured and maintained in T25 flasks, as described above. 
Once a confluent monolayer of cells was established, differentiation was initiated. At 
each experimental time point, cells were rinsed four times with 1.00 mL Ringer’s 
solution containing 5 mM glucose with or without 200 µM isoleucine, leucine, and valine 
(incubation medium). Cells were incubated with 1.00 mL of the corresponding incubation 
medium, for 30 min. After 30 min, the 1.00 mL of incubation medium was removed and 
500 µL of this sample was spiked with 25 µL of 1 mM D-2-amino-adipic-acid (internal 
standard), and used for CE analysis. Cells were removed from the flask walls for protein 
analysis using 1.00 mL of mammalian protein extraction reagent, supplemented with Halt 
Protease Inhibitor Cocktail, EDTA free, and Halt™ Phosphatase Inhibitor Cocktail. 
Flasks incubated with this solution at room temperature until all cells were detached from 
flask walls (5-25 min). This 1.00 mL aliquot was collected for protein quantification 
using a bicinchoninic acid (BCA) assay. 
 Microdialysis Probes 3.3.5
Microdialysis probes were constructed in-house using a side-by-side geometry, as 
described previously.
131
 Briefly, two 40 µm i.d. x 105 µm o.d. fused silica capillaries 
(Polymicro Technologies, Phoenix, AZ) were inserted into a 200 µm i.d. piece of hollow 
fiber dialysis tubing made from regenerated cellulose (13 kD MWCO, Spectrum 
Laboratories, Inc., Rancho Dominguez, CA). A sampling region was created by offsetting 
the capillaries by 1 cm, which was sealed using polyimide resin (Alltech, Deerfield, IL). 
Probes were conditioned prior to use by flushing with ethanol (45µL/h) for five min, 
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followed by ten min of Ringer’s solution (25µL/h). Small molecules diffuse across the 
probe membrane according to a concentration gradient, making microdialysis a useful 
sampling method for biological samples.
54
 
 Online Derivatization 3.3.6
Probes were perfused with Ringer’s solution at 25 µL/h throughout experiments. 
Small molecules diffuse across the probe membrane according to a concentration 
gradient, making microdialysis a useful sampling method for biological samples.
54
 
Dialysate was carried in a 30-40 cm long × 40 µm i.d. × 360 µm o.d. fused silica 
capillary to a 250 µm i.d. stainless steel cross (Valco Instruments Co. Inc, Houston, TX) 
where it was mixed with a 5 µL/h stream of borate buffer and a 5 µL/h stream of 
derivatization solution in order to be fluorescently labeled. Labeling the primary and 
secondary amines with NBD-F allows for LIF detection, giving high sensitivity from 
small concentrations of analytes.
83,91
The derivatization of primary and secondary amines 
took place as the dialysate mixture traveled through a 90 cm long, 75 µm i.d. × 360 µm 
o.d. fused silica capillary from the reaction cross to the flow gate interface; 66 cm of this 
capillary was heated to accelerate the reaction by passing through flexible tubing that was 
circulating water from a water bath at 80°C (NESLAB EX-7 Digital One heating bath 
circulator, Thermo, Newington, NH). The length of the reaction capillary and flow rates 
used resulted in a 5 min reaction time, allowing the labeling reaction to go to 
completion.
90
 Labeling the primary and secondary amines with NBD-F allows for LIF 
detection, giving high sensitivity from small concentrations of analytes.
83,91
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 High-Speed Capillary Electrophoresis (CE)  3.3.7
An 8-8.5 cm long, 10 µm i.d. × 360 µm o.d. fused silica capillary (separation 
capillary) was aligned coaxially (~50 µm apart) with the reaction capillary in  a 
polycarbonate flow gate interface block.
73
 A syringe pump (Pump 22 syringe pump, 
Harvard Apparatus, Holliston, MA) pumped separation buffer at 40 mL/h through this 
gap. Separation buffer flow was stopped using a pneumatically actuated valve (C2-300A 
10 port valve, Valco Instruments Co. Inc., Houston, TX) for 500 ms allowing sample to 
fill the gap. An injection voltage of -13 kV was applied to the exit of the separation 
capillary for 200 ms. After this time, flow through the flow gate is resumed and a 
separation voltage of -19 kV was applied. Injections were controlled by an in-house 
LabView program. Separations were performed every 30 sec. 
 LIF Detection  3.3.8
488 nm argon ion laser was used for LIF detection (150 mW, Melles Griot, 
Carlsbad, CA). The laser beam was passed through a 10× beam expander (Edmond 
Optics, Barrington, NJ), and focused using a 1× lens to a point just past the exit of the CE 
separation capillary in a fused-silica sheath flow cuvette(2 mm square with a 400 µm × 
400 µm square inner bore).
82,135
  Fluorescence emission is collected at 90° with a  60×, 
0.7 NA long working distance objective (Universe Kogaku, Oyster Bay, NJ), filtered 
through spatial (~1 mm diameter) and bandpass filters (543.5 ± 10 nm) (Melles Griot, 
Irvine, CA), and recorded using a photomultiplier tube (PMT R1477, Hamamatsu Corp., 
Bridgewater, NJ). Current from the PMT was amplified (Keithley 428 Current Amplifier, 
Keithley Instruments Inc., Cleveland, OH), filtered with a 10 ms rise time, and recorded 
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using a data acquisition card (National Instruments Corp., Austin, TX). Data analysis was 
performed using Cutter Analysis 7.0.
149
 
 Bicinchoninic Acid (BCA) Assay 3.3.9
Amino acid concentrations were normalized according to cell protein content, as 
measured using a BCA assay. A Pierce™ BCA Protein Assay Kit was used according to 
the included instructions. Briefly, working reagent was prepared by combining “Reagent 
A” and “Reagent B” in a ratio of 50:1 (A: B). 25 µL of each sample or standard was 
pipetted into individual wells of a 96 well plate followed by 200 µL of working reagent; 
all samples were analyzed in triplicate. The plate was gently shaken for 30 s to ensure 
mixing of the working reagent and samples. After shaking, the plate was incubated at 
37°C for 30 min. After incubation, the plate was removed from the incubator and 
absorbance at 562 nm was measured using a plate reader (Spectromax Plus; Molecular 
Devices, LLC, Sunnyvale, CA). A calibration curve was generated from bovine serum 
albumin (BSA) standards. Using this standard curve, protein content for each flask was 
determined and used for normalizing amino acid signals obtained from CE separation. 
 Statistical Analysis 3.3.10
All Figures show mean ±S.E. Differences between groups were assessed using 
Student’s two-tailed t test or two-way ANOVA unless otherwise indicated. *,#, or & 
indicates p-value between 0.01 and 0.05; **, ##, or && indicates p-value <0.01.  
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 Results & Discussion  3.4
3T3-L1 cells were used as a model of adipocytes allowing changes in BCAA 
utilization throughout differentiation to be monitored. 
 3T3-L1 Differentiation  3.4.1
Images were recorded to confirm successful differentiation of 3T3-L1 cells 
Figure 3.1. Microscopic images of 3T3-L1 cells at various time points throughout the 
differentiation process. Cell monolayers were imaged using an inverted phase contrast 
microscope, magnification 20×. “Day 0” (upper left) is prior to any differentiation, but 
confluent; “Day 2” (upper right) is after 48 hour of incubation with DMEM, FBS, 
IBMX, dexamethasone, ciglitazone, and insulin; “Day 4” (lower left) is 48 hour after 
“Day 2” when media contains DMEM, FBS, and insulin; and finally, “Day 14” (lower 
right) is 14-16 days after the start of differentiation. 
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(Figure 3.1). 3T3-L1 cells were cultured in T-25 flasks until confluency was reached. 
Differentiation of 3T3-L1 cells is induced by the addition of ciglitazone, insulin, IBMX, 
and dexamethasone after cells achieved confluency. Cells were imaged at four stages 
throughout differentiation, as described previously. Figure 3.1-0 (upper left) shows a 
confluent monolayer of cells with a normal, pre-differentiation fibroblast-like 
appearance. Figure 3.1-2 (upper right) shows the cells 2 days after the induction of 
differentiation. At this point, the cells still have a fibroblast-like appearance, with little 
change in confluency. Figure 3.1-4 (lower left) shows the cells 4 days after the induction 
of differentiation, and 2 days after the removal of IBMX, ciglitazone, and dexamethasone 
from the cell culture medium. At this point, the cells continue to have a fibroblast-like 
appearance, with a few flasks showing signs of lipid accumulation. After 14-16 days, the 
cells show accumulation of lipids. Lipid accumulation is fast at the beginning, and slows 
over the final 8-10 days. Figure 3.1-14 (lower right) shows successful differentiation with 
approximately 95% of cells showing lipid accumulation. 
 BCAA Efflux 3.4.2
Utilization of BCAAs changes throughout the course of differentiation, as 
previously demonstrated.
30
 As 3T3-L1 cells differentiate, the need for lipogenic amines 
increases as cells being to accumulate lipids. Figure 3.2 shows example 
electropherograms collected from 3T3-L1 cells that have been incubated in Ringer’s 
solution with 5 mM glucose for 30 min on Day 0 and Day 14. The cells released many 
amines above the high-speed CE instrument’s limits of detection. Utilization of BCAAs 
was modified as the cells released fewer BCAAs on Day 14 (red) compared to Day 0 
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(black). Peaks were identified by 
transferring the microdialysis 
probe between a vial containing 
the cell sample, to a vial 
containing individual standards, 
then returning the probe back to 
the cell sample vial. In total, 17 
amino acids can be identified in a 
~20 second separation window. 
Peaks identified include: lysine, 
isoleucine, leucine, ornithine, 
methionine, phenylalanine, 
valine, ornithine, GABA, 
glutamine, alanine, threonine, β-
alanine, glycine, taurine, 
glutamate, and aspartate.  
Figure 3.3 shows the release of the BCAAs at each stage of differentiation. Less 
release of all three BCAAs during periods of high lipogenesis is observed. Lipogenesis is 
expected to occur most rapidly 4 days after the induction of differentiation. Statistical 
differences in release of BCAAs is observed between Day 0 and Day 14 for isoleucine 
and leucine, while statistical differences in release of leucine and valine show differences 
between Day 0 and Day 4. All three BCAAs show statistical differences in release 
Figure 3.2. Butterfly plot of electropherograms 
comparing NBD-F labeled amino acids released from 
3T3-L1 cells incubated with Ringer’s solution 
containing 5 mM glucose at Day 0 (top) and Day 14 
(bottom) of the differentiation process. Peak 
intensities and relative ratios of amines show changes 
in release profiles. Peak identities are:  (1) lysine, (2) 
isoleucine, (3) leucine, (4) ornithine, (5) methionine, 
(6) phenylalanine, (7) valine, (8) ornithine, (9) 
GABA, (10) glutamine, (11) alanine, (12) threonine, 
(13) β-alanine, (14) glycine, (15) hydrolysis product, 
(16) taurine, (17) internal standard, (18) glutamate, 
(19) aspartate. 
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between Days 2 and 4. In 
agreement with the BCAAs, the 
downstream lipogenesis marker 
glutamine, as shown in Figure 
3.4A (red), has increased release 
during periods of increased 
lipogenesis, 2 days after 
differentiation was started, and 
continuing until at least 4 days 
after differentiation induction. 
However, the release profile of 
alanine contradicts these findings. 3T3-L1 adipocytes release less alanine throughout 
differentiation, including 4  
days after differentiation was induced, as shown in Figure 3.4B, in red. Glutamate 
(Figure 3.4C, red) shows a similar pattern to alanine over the course of differentiation. 
These observations could be due to a shift in equilibrium of BCAA catabolism 
byproducts to generate tricarboxylic acid (TCA) cycle and fatty acid synthesis precursor 
molecules in order to make acetyl CoA products (Figure 1.2), and a lack of available 
pyruvate. When lipid accumulation has stabilized, as on Day 14, increased release of 
glutamine, alanine, and glutamate is observed, compared to Day 4. The changes in  
 
Figure 3.3. Release of BCAAs at each stage of 
differentiation when incubated with Ringer’s solution 
containing 5 mM glucose for 30 minutes at different 
points during differentiation. Error bars are SEM; 
n=3. *, p-value < 0.05, **, p-value < 0.01. 
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Figure 3.4. Rate of 
glutamine (A), alanine 
(B), and glutamate (C) 
release by 3T3-L1 cells 
incubated with Ringer’s 
solution + 5 mM glucose 
without (Red) and with 
(Blue) 200 µM isoleucine, 
leucine, and valine, 
throughout the 
differentiation process. 
Concentrations were 
normalized using an IS 
and to cell protein content 
as determined by the BCA 
assay. *, p-value < 0.05, 
**, p-value < 0.01. 
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utilization of BCAAs and downstream metabolites reflect changes in energy needs of the 
cells throughout the course of differentiation. 
 BCAA Uptake throughout Differentiation  3.4.3
Although BCAA efflux followed expected patterns; release of downstream 
markers of lipogenesis did not follow expected patterns. In an effort to assess required 
substrates for lipid accumulation, a follow-up experiment was conducted. Cells were 
incubated in Ringer’s 
solution contacting 5 mM 
glucose with 200 µM of 
each BCAA, in order to 
assess the patterns of 
lipogenesis in 3T3-L1 
adipocytes as a function of 
BCAA presence, as the 
cells differentiate from pre-
adipocytes to fully mature 
adipocytes. Figure 3.5 
shows electropherograms 
collected from 3T3-L1 
cells that have been 
incubated in this solution; 
peak intensities have 
Figure 3.5. Butterfly plot of electropherograms comparing 
NBD-F labeled amino acids released from 3T3-L1 cells 
incubated with Ringer’s solution containing 5 mM glucose 
and 200 µM isoleucine, leucine, and valine at Day 2 (top) 
and Day 14 (bottom) of the differentiation process. Peak 
intensities and relative ratios of amines show changes in 
release profiles. Peak identities are:  (1) lysine, (2) 
isoleucine, (3) leucine, (4) ornithine, (5) methionine, (6) 
phenylalanine, (7) valine, (8) ornithine, (9) GABA, (10) 
glutamine, (11) alanine, (12) threonine, (13) β-alanine, (14) 
glycine, (15) hydrolysis product, (16) taurine, (17) internal 
standard, (18) glutamate. 
 
  62 
changed throughout the 
course of differentiation. 
Relative peak heights are 
changed when 
comparing the net flux at 
Day 2 (top) and Day 14 
(bottom). As shown in 
Figure 3.6, the uptake of 
BCAAs into the cells did 
not change statistically 
over the course of 3T3-
L1 cell differentiation. 
Downstream 
metabolites, alanine, glutamine, and glutamate, however, did show statistical differences 
in release as the cells progress through differentiation, shown in blue in Figure 3.4. 
Previous studies have shown that differentiated adipocytes have increased catabolism of 
BCAAs, as compared to undifferentiated cells.
30
 Our results agree with this and are 
evidenced by the accumulation of lipid vesicles (Figure 3.1-14). These experimental 
results suggest that BCAA flux (Figure 3.6) slows once cells are fully differentiated, as 
the need for energy storage decreases. The BCAA flux and downstream markers alanine 
and glutamate are in agreement with this observation (Figure 3.4A and Figure 3.4B, 
blue). 
Figure 3.6. Uptake of BCAAs at each stage of differentiation 
when incubated with Ringer’s solution containing 5 mM 
glucose and 200 µM BCAAs for 30 minutes, at different 
points during differentiation. Error bars are SEM; n=3. No 
statistical differences were observed. 
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 Differences in Release of Dowstream Metabolites 3.4.4
When comparing the relative amounts released between experiments, there is a 
150% increase in released alanine, 2 days after the induction of differentiation, and 
300%+ increase in released alanine 4 days after differentiation is initiated. Similar trends 
are seen in Figure 3.4A and Figure 3.4C, for glutamine and glutamate. Glutamine had 
statistically more release throughout all stages when comparing flasks that did or did not 
contain BCAAs in the incubation medium. All stages had over 225% relative increase for 
glutamine. Glutamate saw similar trends, except at the first stage, Day 0, which was not 
statistically different between the two experiments. These relative increases in 
downstream metabolites between experiments suggest that the presence of BCAAs 
promotes lipogenesis in 3T3-L1 adipocytes. 
 Conclusions 3.5
BCAA flux and BCAA effects on 3T3-L1 lipogenesis has been measured using 
online high-speed CE-LIF. Using this assay, in conjunction with microdialysis sampling, 
allows for high-throughput measurements of many small molecule amines from cell 
samples. This assay has shown its ability to measure lipogenesis in 3T3-L1 cells, by 
monitoring lipogenesis markers (alanine, glutamine, and glutamate), as well as monitor 
adipocyte signaling through the release of amino acids. Using this assay, we have been 
able to see that the rate of lipogenesis is fastest ~4 days after differentiation is initiated 
and slows once cells have fully accumulated lipids, about 14-16 days after differentiation 
is started. The effect of excess BCAAs on lipogenesis can be seen by changes in the 
release of the downstream metabolites, as there is more release as the cells progress 
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through the stages of differentiation. The techniques used here can be used to measure 
many other small molecule analytes from various cell types, in vitro, as well as in vivo, 
including changes under whole body or local stimulation.  
  65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4: Effect of Glucose and Branched Chain Amino Acids 
on Lipogenesis throughout Differentiation of 3T3-L1 Adipocytes 
  66 
 Summary 4.1
Lipogenesis was monitored in 3T3-L1 adipocytes over the course of 
differentiation when cells were incubated with varying concentrations of glucose. 
Alanine, glutamine, and glutamate, downstream metabolites of lipogenesis were 
monitored, as well as isoleucine, leucine, and valine uptake and release. Amino acids 
were monitored using online microdialysis-capillary electrophoresis with laser induced 
fluorescence detection (CE-LIF). The effect of various glucose concentrations (0-20 mM) 
was assessed at various stages in the 3T3-L1 differentiation process. BCAA release is 
lowest on Day 4 of differentiation, as expected, when lipid accumulation is most rapid. 
BCAA uptake is highest, under most conditions, on Day 2 or Day 4, when lipid 
accumulation is most rapid. Efflux of downstream metabolites are in agreement with this 
observation, with alanine, glutamine, and glutamate having the most release on Day 2 or 
Day 4. No significant trends were observed when examining how incubation with 
glucose affects lipogenesis at each step in the differentiation process.  
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 Introduction  4.2
BCAAs are known to play a role in signaling throughout the body.
29,137-139
 
Circulating BCAA concentrations relay information about energy balance from adipose 
tissue to other organs. As a result, energy related functions are regulated, including 
appetite control, glucose metabolism, and insulin secretion.
14-16,150
 Previous studies have 
shown that adipose tissue regulates circulating BCAA concentrations through uptake and 
lipogenesis. BCAAs may be involved in many other cellular processes as BCAA 
receptors can be found throughout the body. Individuals who are overweight or obese 
have increased circulating BCAA levels.
26,116,151
  Dysregulation of BCAA metabolism 
has been seen in many diseased states and is oftentimes associated with impaired glucose 
metabolism and type 2 diabetes.
152,153
 
Under normal conditions, glucose metabolism is a highly regulated process and is 
the primary energy source for many biological processes. Glucose metabolism is 
regulated by many factors, including insulin,
154-157
 glucagon,
157,158
 and glucagon-like 
peptide-1
157,159
. Nishitani, et al. found that BCAAs regulated and improved the 
metabolism of glucose in rats with liver cirrhosis by promoting glucose uptake in skeletal 
muscle.
160
  
A high speed capillary electrophoresis (CE) assay was previously developed in 
order to monitor changes in the uptake and release of branched chain amino acids 
(BCAAs). This assay has also proven to be useful for measuring the release of 
downstream markers of lipogenesis, including alanine, glutamine, and glutamate. Using 
this assay, we can measure how biologically relevant stimuli, such as glucose, influence 
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the uptake and release of BCAAs, as well as the release of the downstream metabolites, 
thus providing a good assay for measuring lipogenesis in 3T3-L1 adipocytes.  
We wanted to investigate how local glucose concentrations affect the metabolism 
of BCAAs, over the course of differentiation of the 3T3-L1 model cell line. In order to do 
so, we first looked at glucose’s effect on 3T3-L1 cells and lipogenesis. Glucose 
concentrations were varied (0-20 mM) to see if lipogenesis changed as a function of local 
glucose concentration, at varying stages of maturation. BCAA and downstream 
metabolite efflux was measured at each stage of differentiation. A follow-up experiment 
monitored changes in the uptake of BCAAs after incubation with varying glucose 
concentrations (0-20 mM) and 200 µM BCAAs. By monitoring changes in downstream 
metabolites, alanine, glutamine, and glutamate, we can provide insight into how local 
BCAA and glucose concentrations affect lipogenesis.  
 Experimental 4.3
 Chemicals and Reagents 4.3.1
Ciglitazone was purchased from VWR International (Radnor, Pennsylvania). α-
cyclodextrin (α-CD) was purchased from CTD Holdings, Inc. (technical grade, Alachua, 
FL). Dulbecco’s Modified Eagle’s Medium (DMEM), newborn calf serum (NCS), fetal 
bovine serum (FBS), and penicillin-streptomycin (5,000U/mL) were purchased from 
Invitrogen Molecular Probes (Eugene, OR). D-glucose, Mammalian Protein Extraction 
Reagent (M-PER®), Halt Protease Inhibitor Cocktail, EDTA free, Halt™ Phosphatase 
Inhibitor Cocktail, and sodium borate tetrahydrate were purchased from Fisher Scientific 
(Waltham, MA). 3-Isobutyl-1-methylxanthine (IBMX), dexamethasone, insulin (human), 
and all amino acids were purchased from Sigma-Aldrich (St. Louis, MO).Trypsin 
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solution (0.25% Trypsin/0.53mM EDTA in Hank’s Balanced Salt Solution) was 
purchased from ATCC (Manassas, VA). Phosphate-buffered saline (PBS, 10×) was 
purchased from Bio-Rad Laboratories (Hercules, CA). 4-Fluoro-7-Nitro-2, 1, 3-
Benzoxadiazole (NBD-F) was purchased from TCI America (Portland, OR). 
 Buffers and Solutions 4.3.2
All solutions were prepared in deionized water (Milli-Q, 18.2 MΩ; Millipore, 
Bedford, MA) and filtered (0.22µm) unless otherwise noted. Stock standard solutions (1 
mM) of amino acids were prepared in Ringer’s solution. Ringer’s solution was prepared 
with 123 mM NaCl, 1.5 mM CaCl2, and 5 mM KCl, adjusted to pH 7.5; and autoclaved 
for sterilization. Ringer’s solution containing glucose (0, 5, 10, 15, and 20 mM) was 
prepared with 123 mM NaCl, 1.5 mM CaCl2, and 5 mM KCl, adjusted to pH 7.5; and 
autoclaved for sterilization. Sheath flow buffer contained 90 mM borate adjusted to pH 
9.8. CE separation buffer contained 90 mM borate/35 mM α-cyclodextrin adjusted to pH 
9.8. Derivatization solution was prepared daily by dissolving NBD-F (4-fluoro-7-nitro-
2,1,3-benzoxadiazole; TCI America, Portland, OR) in methanol and diluting with equal 
parts 500 µM HCl and degassing under vacuum, giving a final solution of 20 mM NBD-
F/250 µM HCl in 1:1 methanol: water.  
 Cell Culture 4.3.3
3T3-L1 fibroblasts (ATCC® CL-173™) were maintained in 25 cm2 tissue culture 
flasks containing 8 mL of high glucose DMEM supplemented with 10% NCS and 1% 
penicillin/streptomycin. Cultures were maintained in a 37° C incubator (5% CO2). 3T3-
L1 cells were differentiated using methods previously described.
44
 Briefly, differentiation 
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was induced by adding high glucose DMEM containing 10% FBS, 0.5 mM IBMX, 0.25 
µM dexamethasone, 2 µM ciglitazone, and 170 µM insulin. IBMX, ciglitazone, and 
dexamethasone were removed after 2 days; insulin was removed after 4 days. 
Maintenance media (high glucose DMEM, 10% FBS, and 1% penicillin/streptomycin) 
was used after 4 days. Experiments were conducted at 4 different time points—“Day 0” 
is prior to any differentiation, but confluent; “Day 2” is after 48 h of incubation with 
DMEM, FBS, IBMX, dexamethasone, ciglitazone, and insulin; “Day 4” is 96 h after 
differentiation induction, when media contains DMEM, FBS, and insulin; and finally, 
“Day14” is 14-16 days after the induction of differentiation.   
 Measuring Bulk Amino Acid Release/Uptake 4.3.4
3T3-L1 cells were cultured and maintained in T25 flasks, as described above. 
Once a confluent monolayer of cells was established, differentiation was initiated.. At 
each corresponding time point, cells were rinsed four times with Ringer’s solution 
containing 5 mM glucose with or without 200 µM isoleucine, leucine, and valine 
(incubation medium). Cells were incubated with 1.00 mL of the corresponding incubation 
medium, for 30 min. After 30 min, the 1.00 mL of incubation medium was removed and 
500µL of this sample was spiked with 25 µL of 1 mM D-2-amino-adipic-acid (internal 
standard), and was used for online microdialysis- CE analysis. Cells were removed from 
the flask walls for protein analysis using 1.00 mL of mammalian protein extraction 
reagent, supplemented with Halt Protease Inhibitor Cocktail, EDTA free, and Halt™ 
Phosphatase Inhibitor Cocktail. Flasks incubated with this solution at room temperature, 
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until all cells were detached from flask walls (5-25 min). This 1.00 mL aliquot was 
collected for protein quantification using a bicinchoninic acid (BCA) assay. 
 Microdialysis probes 4.3.5
Microdialysis probes were constructed in-house using a side-by-side geometry, as 
described previously
131
. Briefly, two 40 µm i.d. x 105 µm o.d. fused silica capillaries 
(Polymicro Technologies, Phoenix, AZ) were inserted into a 200 µm i.d. piece of hollow 
fiber dialysis tubing made from regenerated cellulose (13 kD MWCO, Spectrum 
Laboratories, Inc., Rancho Dominguez, CA). A sampling region was created by offsetting 
the capillaries by 1 cm, and sealing using polyimide resin (Alltech, Deerfield, IL). Probes 
were conditioned prior to use by flushing with ethanol (45µL/h) for five min, followed by 
ten min of Ringer’s solution (25µL/h). Probes were perfused with Ringer’s solution at 25 
µL/h throughout experiments. 
 Online Derivatization  4.3.6
Dialysate was carried in a 30-40 cm long × 40 µm i.d. × 360 µm o.d. fused silica 
capillary to a 250 µm i.d. stainless steel cross (Valco Instruments Co. Inc, Houston, TX) 
where it was mixed with a 5 µL/h stream of borate buffer and a 5 µL/h stream of 
derivatization solution. The derivatization of primary and secondary amines took place as 
the dialysate mixture traveled through a 90 cm long, 75 µm i.d. × 360 µm o.d. fused silica 
capillary from the reaction cross to the flow gate interface; 66 cm of this capillary was 
heated to accelerate the reaction by passing through flexible tubing that was circulating 
water from a water bath at 80°C (NESLAB EX-7 Digital One heating bath circulator, 
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Thermo, Newington, NH). The length of the reaction capillary and flow rates used 
resulted in a 5 min reaction time, allowing the labeling reaction to go to completion.
90
 
 High Speed Capillary Electrophoresis  4.3.7
An 8-8.5 cm long, 10 µm i.d. × 360 µm o.d. fused silica capillary (separation 
capillary) was aligned coaxially, with a 50 µm gap, with the reaction capillary in  a 
polycarbonate flow gate interface block.
73
 A syringe pump (Pump 22 syringe pump, 
Harvard Apparatus, Holliston, MA) pumped separation buffer at 40 mL/hthrough this 
gap. Separation buffer flow was controlled by a pneumatically actuated valve (C2-300A 
10 port valve, Valco Instruments Co. Inc., Houston, TX); crossflow of the separation 
buffer was stopped to for 500 ms allowing a sample plug to build up in the gap. An 
injection voltage of -13 kV was applied to the exit of the separation capillary for 200 ms. 
The flow stream though the flow gate was resumed and a separation voltage of -19 kV 
was applied. Separations were performed every 30 s. Injections were controlled by an in-
house LabVIEW program.  
 LIF Detection  4.3.8
A 488 nm argon ion laser was used for LIF detection (150 mW, Melles Griot, 
Carlsbad, CA). The laser beam was passed through a 10× beam expander (Edmond 
Optics, Barrington, NJ), and focused using a 1× lens to a point just past the exit of the CE 
separation capillary in a fused-silica sheath flow cuvette(2 mm square with a 400 µm × 
400 µm square inner bore).
82,135
 Fluorescence emission is collected at 90° with a  60×, 0.7 
NA long working distance objective (Universe Kogaku, Oyster Bay, NJ) and filtered 
through spatial (~1 mm diameter) and bandpass filters (543.5 ± 10 nm) (Melles Griot, 
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Irvine, CA), and recorded using a photomultiplier tube (PMT R1477, Hamamatsu Corp., 
Bridgewater, NJ). Current from the PMT was amplified (Keithley 428 Current Amplifier, 
Keithley Instruments Inc., Cleveland, OH), filtered with a 10 ms rise time, and recorded 
using a data acquisition card (National Instruments Corp., Austin, TX). Data analysis was 
performed using Cutter Analysis 7.0.
149
 
 Bicinchoninic Acid (BCA) Assay 4.3.9
Amino acid concentrations were normalized according to cell protein content, as 
measured using a BCA assay. A Pierce™ BCA Protein Assay Kit was used according to 
included instructions. Briefly, working reagent was prepared by combining “Reagent A” 
and “Reagent B” in a ratio of 50:1 (A: B). 25 µL of each sample or standard was pipetted 
into individual wells of a 96 well plate followed by 200 µL of working reagent; all 
samples were analyzed in triplicate. The plate was gently shaken for 30 s to ensure 
mixing of the working reagent and samples. After shaking, the plate was incubated at 
37°C for 30 min. After incubation, the plate was removed from the incubator and 
absorbance at 562 nm was measured using a plate reader (Spectromax Plus; Molecular 
Devices, LLC, Sunnyvale, CA). A calibration curve was generated from BSA standards. 
Using this standard curve, protein content for each flask was determined and used for 
normalizing amino acid signals obtained from CE separation. 
 Statistical Analysis 4.3.10
All Figures show mean ±S.E. Differences between groups were assessed using 
Student’s two-tailed t test.  
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 Results & Discussion 4.4
 Amino Acid Efflux in the Presence of Glucose 4.4.1
4.4.1.1 BCAA Efflux  
Through catabolism of BCAAs, acetyl-CoA products are generated (Figure 1.2). 
During periods of low energy, these products are directed and used in the TCA cycle for 
generation of ATP. During periods of high energy, the acetyl-CoA products are used in 
fatty acid synthesis and are then stored as triglycerides in lipid vesicles in the cytoplasm 
of adipocytes. As the cells progress through differentiation, cellular needs change, and at 
later stages, the cells rapidly accumulate lipids. This rapid accumulation of lipids leads to 
increased utilization of BCAAs, compared to earlier stages. BCAA release was 
monitored over the course of 3T3-L1 cell differentiation into mature adipocytes to 
monitor these changes in energy usage, when incubated with various concentrations of 
glucose for 30 min. As shown in Figure 4.1, 3T3-L1 cells released the most isoleucine at 
early stages in the maturation process (Day 0 & 2) and released the least isoleucine 
during times of rapid lipid accumulation (Day 4). The same trend was seen at all glucose 
concentrations administered (0-20 mM; Figure 4.1A-E). For all glucose concentrations, 
the release of isoleucine on Day 4 was statistically different (p<0.05) from earlier 
developmental stages (Day 0 & 2), however, was not statistically different than the fully 
differentiated state, Day 14, as shown in Figure 4.1A-E.  
Utilization of leucine and valine showed similar patterns. The least efflux of 
leucine and valine from 3T3-L1 cells occurred on Days 4 & 14, regardless of local 
glucose concentration (Figure 4.2A). The observed results support previous research by 
Green, et al. suggesting that consumption of BCAAs increases as the cells progress  
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Figure 4.1. Rate of isoleucine release at each 
stage of differentiation by 3T3-L1 cells 
incubated with Ringer’s solution and varying 
concentrations of glucose: (A) 0 mM, (B) 5 
mM, (C) 10 mM, (D) 15 mM, and (E) 20 mM. 
Rates were normalized to cell protein content 
as determined by BCA assay. Error bars are SE 
for n=3 samples. 
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through differentiation, as is shown in Figure 4.1. 
30
 BCAAs can be catabolized to 
generate fatty acid synthesis and TCA cycle precursor molecules.  
When looking at the release of BCAAs based on developmental stage, we see 
very little changed in released 
isoleucine (Figure 4.3), 
regardless of the local 
glucose concentration. When 
the cells are in the pre-
adipocyte stage (Day 0; A in 
Figure 4.3), the most 
isoleucine release occurs at 5 
& 10 mM glucose; however, 
this is not the case once the 
cells have progressed further 
into the differentiated state. 
Once the 3T3-L1 cells are 
more committed to the 
differentiated state, the least 
amount of isoleucine release 
occurs at 5 & 10 mM glucose 
(Figure 4.3B,C, & D). This 
trend holds true from Day 2  
Figure 4.2. (A) Rate of BCAA release from 3T3-L1 
after incubation with 15 mM glucose, at each stage of 
differentiation. Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE 
for n=3 samples. (B) Rate of BCAA release from 3T3-L1 
cells after incubation with varying concentrations of 
glucose, on Day 14. Rates were normalized to cell 
protein content as determined by BCA assay. Error bars 
are SE for n=3 samples. 
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through Day 14, as depicted in Figure 4.3B-D. The trends seen in isoleucine are the same 
as what is seen when analyzing the release patterns of leucine and valine as well. Figure 
4.2B shows the release of all 3 BCAAs on Day 14, showing that at biologically relevant 
concentrations of glucose, 3T3-L1 cells release the least amount of BCAAs. Higher local 
concentrations of glucose appear to promote glycolysis rather than BCAA catabolism, as 
utilization of BCAAs is decreased at these concentrations. 
Figure 4.3. Rate of isoleucine release from 3T3-L1 cells after incubation with 
Ringer’s solution and varying concentrations of glucose (0-20 mM) at each stage 
of differentiation: (A) Day 0, (B) Day 2, (C) Day 4, (D) Day 14. Amounts were 
normalized to cell protein content as determined by BCA assay. Error bars are SE 
for n=3 samples. 
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4.4.1.2 Downstream Metabolite Efflux  
In order to see if changes in BCAA release correspond to increases in catabolism 
of BCAAs and thus, increases in lipogenesis, we tracked the release of downstream 
metabolites, alanine, glutamate, and glutamine. 3T3-L1 cells released the most alanine at 
Day 0, when the cells are in the earliest stages of maturation (Figure 4.4, black). This 
contradicts what we would expect, as we would expect very little lipid accumulation to 
be occurring at this time point, as cells have just begun differentiation. At stages when 
lipogenesis is expected to be highest (i.e. Day 4), alanine release is lowest, which is 
again, the opposite of what is expected. This could be attributed to a lack of upstream 
BCAAs to catabolize, or a lack of available pyruvate to convert glutamate to alanine. 
Pyruvate is generated through the metabolism of glucose through the process of 
glycolysis. The same trend is seen at all glucose concentrations assessed, indicating that 
extracellular glucose alone does not promote BCAA catabolism (Figure 4.4A-E, black).  
Glutamine and glutamate have similar trends (Figure 4.5B & 4.5C), however, 
once cells have fully matured, the glutamate/glutamine pathway seems to be affected by 
the glucose concentration. At 15 mM glucose, glutamine release at Day 14 drops to 
nearly 0 net release, while glutamate release increases dramatically, as shown in black in 
Figure 4.5B & 4.5C. This trend is also seen at 10 mM and 20 mM glucose concentrations. 
When looking at the release trends as a function of glucose concentration, alanine has the 
most release at Day 0, when the cells were incubated with 5 or 10 mM glucose. Day 2 has 
the most release when incubated with 0 mM glucose, with the least release at 5 mM;  
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Figure 4.4. Rate of alanine release at 
each stage of differentiation by 3T3-L1 
cells incubated with Ringer’s solution, 
with (red) and without (black) 200 µM 
BCAAs, and varying concentrations of 
glucose: (A) 0 mM, (B) 5 mM, (C) 10 
mM, (D) 15 mM, and (E) 20 mM. Rates 
were normalized to cell protein content 
as determined by BCA assay. Error bars 
are SE for n=3 samples 
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there appears to be an upward trend in the 
release, with all higher glucose 
concentrations having more release the 
previous concentration (from 5 mM), as 
shown in Figure 4.6 (black). On Day 4, 
there is no trend in the release of alanine 
over the range of glucose concentrations. 
Once the cells have fully matured, Day 14, 
alanine is released the most when 
incubated without glucose, indicating that 
catabolism of BCAAs may be occurring.  
Similar trends are seen when 
looking at glutamine and glutamate release 
at Day 0. Glutamate has the same trend on 
Day 2 as alanine, but glutamine does not; 
glutamine has the most release when 
incubated with 20 mM glucose. Day 4 has 
similar trends when looking at all three 
downstream metabolites, while Day 14 has 
unusual trends in glutamine and glutamate 
as discussed previously.  
Figure 4.5. Release of downstream 
metabolites, alanine, glutamate, and 
glutamine at each stage of differentiation 
when 3T3-L1 cells are incubated with 
Ringer’s solution containing 15 mM glucose 
with (red) or without (black) 200 µM 
BCAAs for 30 minutes. Error bars are SEM; 
n=3. 
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 Amino Acid Efflux in the Presence of Glucose and 200 µM BCAAs 4.4.2
4.4.2.1 BCAA Uptake  
In order to determine if local BCAA concentrations influence glucose and its 
effect on 3T3-L1 lipogenesis, 3T3-L1 cells were incubated with 200 µM BCAAs for 30 
min. Amino acid release from those 3T3-L1 cells was monitored throughout  
Figure 4.6. Rate of alanine release after incubation with varying concentrations of 
glucose, at each stage of differentiation, by 3T3-L1 cells incubated with Ringer’s 
solution, with (red) and without (black) 200 µM BCAAs, and varying concentrations of 
glucose (0-20 mM): (A) Day 0, (B) Day 2, (C) Day 4, (D) Day 14. Amounts were 
normalized to cell protein content as determined by BCA assay. Error bars are SE for 
n=3 samples. 
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Figure 4.7. Rate of leucine uptake at 
each stage of differentiation by 3T3-
L1 cells incubated with Ringer’s 
solution, 200 µM BCAAs, and 
varying concentrations of glucose: 
(A) 0 mM, (B) 5 mM, (C) 10 mM, 
(D) 15 mM, (E) 20 mM. Rates were 
normalized to cell protein content as 
determined by BCA assay. Error bars 
are SE for n=3 samples. 
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differentiation with varying doses of glucose. Figure 4.7 shows changes and trends 
observed for leucine after incubation with various glucose concentrations (0-20 mM) and 
200 µM BCAAs for 30 min. When 3T3-L1 cells are incubated with 0 mM glucose and 
200 µM BCAAs, the most uptake occurs on Day 2 (Figure 4.7C). The same trend is 
observed at 5, 10, and 15 mM glucose concentrations as well. At 20 mM glucose, 
however, the most uptake 
of leucine occurs on Day 
4, during the peak of 
lipogenesis (Figure 
4.7E). Overall patterns 
and trends are similar for 
isoleucine and valine, 
with most uptake 
occurring on either Day 2 
or Day 4, regardless of 
the glucose concentration 
present during 
incubation. Figure 4.8 shows the uptake of all three BCAAs over the course of 
development after incubation with 10 mM glucose and 200 µM BCAAs. 
Figure 4.8. Uptake of BCAAs at each stage of differentiation 
when 3T3-L1 cells are incubated with Ringer’s solution 
containing 200 µM BCAAs and 10 mM glucose for 30 
minutes. Error bars are SEM; n=3. 
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The effects of glucose and BCAA concentrations on 3T3-L1 adipocytes can be 
monitored as a function of differentiation state (Figure 4.9). At the earliest stage of 
differentiation, Day 0 (Figure 4.9A), 3T3-L1 cells had the most uptake of isoleucine at 0 
mM, with the least amount of uptake at 10 mM. Day 2 (Figure 4.9B) had the most uptake 
of isoleucine at 15 mM, while Day 4 (Figure 4.9C) & 14 (Figure 4.9D) had the most 
isoleucine uptake at 0 mM, similar to Day 0. All four time points had the least release 
when incubated with 10 mM glucose. Leucine and valine have similar trends, except on 
Day 2, with 20 mM glucose, as valine had net release, rather than uptake. Uptake of 
Figure 4.9 Rate of isoleucine uptake from 3T3-L1 cells after incubation in Ringer’s 
solution with varying concentrations of glucose (0-20 mM) and 200 µM isoleucine, 
leucine, and valine, at each stage of differentiation: (A) Day 0, (B) Day 2, (C) Day 4, (D) 
Day 14. Amounts were normalized to cell protein content as determined by BCA assay. 
Error bars are SE for n=3 samples. 
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BCAAs on Day 4, when cells are undergoing lipogenesis most rapidly, looking at trends 
in glucose concentration is shown in Figure 4.10.These data suggest that glucose 
concentration affects 3T3-L1 cells differently at different maturation stages.  
4.4.2.2 Alanine, Glutamate & Glutamine Release  
Monitoring alanine, glutamate, and glutamine allows us to monitor lipogenesis as 
a function of BCAA 
presence. As shown 
in Figure 4.5A, 
alanine release is 
highest on Day 2 
after incubation with 
15 mM glucose and 
BCAAs; the same is 
true after incubation 
with 20 mM glucose 
and BCAAs as well. 
The release of 
glutamine and glutamate follow similar trends to alanine at each glucose concentration, 
however, there appears to be equilibrium between glutamine and glutamate that is 
maintained. As shown in Figure 4.5C, when glutamine concentrations decrease on Day 4, 
glutamate concentrations increase (Figure 4.5B), at all glucose concentrations assessed. 
Alanine has the most release on Day 2, glutamine has the most release at Day 2 & 4, 
Figure 4.10. Uptake of BCAAs on Day 4 when incubated with 
Ringer’s solution containing 200 µM BCAAs and varying 
concentrations of glucose (0-20 mM) for 30 minutes. Error bars 
are SEM; n=3. 
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while glutamate has the most release on Day 4, when incubated with 0 mM glucose and 
200 µM BCAAs. 5 mM glucose gives the most release of alanine and glutamate at Day 4, 
Day 2 & 14 have the most release of glutamine. When 3T3-L1 cells are incubated in 10 
mM glucose and 200 µM BCAAs, alanine and glutamine have the most release on Day 2 
of the differentiation process, while glutamate is released the most on Day 4. The trends 
seen in the downstream metabolites correspond closely with the patterns observed in the 
uptake of BCAAs at similar glucose concentrations. No significant trends can be 
deciphered when analyzing the downstream metabolites based on cells’ maturation stage. 
Fluctuations in release of downstream metabolites are observed, however, the 
observations do not follow expected results. This could be due to interactions with 
glucose and its effects on lipogenesis in 3T3-L1 cells. 
 Comparing incubation with and without BCAAs 4.4.3
Comparing the results between the experiments performed when cells were 
incubated with circulating levels of BCAAs to those when cells were not, allows use to 
determine the effects of the BCAAs on lipogenesis. Examining these results also allows 
us to assess their influence on lipogenesis throughout the differentiation process, while 
monitoring changes in lipogenesis markers, as a function of local glucose concentration.  
When comparing the two experiments, looking at the development of the cells, 
throughout the differentiation process, at each glucose concentration, we see that alanine 
has the opposite trend when the BCAAs are present, as shown in Figure 4.4A-E. We can 
see that no matter what the local glucose concentration was, the cells released the most 
alanine during the intermediate stages of development, Days 2 & 4, when incubated with 
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200 µM BCAAs (red), and the least amount of alanine is released on Day 4 when the 
cells are incubated in Ringers solution without BCAAs (black). Between experiments, 
there is a 180% increase, on average, in the total alanine released on Day 2, and a 300%+ 
increase on Day 4. Increases in glutamine and glutamate are even larger, but trends hold 
true for both of those amino acids (see Appendix, Figure A.8). When looking at the 
experiments and how the glucose concentration affects the release, as a function of 
differentiation stage, we see that there are no statistically significant trends for any of the 
downstream lipogenesis markers (See Figure 4.6A-D). It could be argued that on Days 2 
& 4, the cells release more alanine, glutamine, and glutamate, regardless of local glucose 
concentration, solely due to the nature of the stage of differentiation that the cells are in. 
These intermediate stages are when cells are accumulating lipids and catabolize BCAAs 
most rapidly. 
 Conclusion 4.5
Changes in BCAA uptake and release as a function of local glucose and BCAA 
concentration was monitored using an online high-speed CE-LIF assay. This assay allows 
the BCAAs, as well as downstream metabolites, alanine, glutamine, and glutamate, to be 
monitored to assess changes in release patterns based on local glucose and BCAA 
concentrations. Using this assay, we were able to observe different lipogenic processes as 
cells progress through differentiation. Downstream metabolites suggest that 3T3-L1 cells 
are accumulating lipids and doing so by catabolism of BCAAs. When cells were 
incubated with Ringer’s solution containing only glucose (0-20 mM), BCAA release 
diminished as the cells accumulated more lipids, while alanine, glutamine, and glutamate 
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release did not follow expected increasing trends. This gives evidence that BCAA 
catabolism was not the only mechanism behind lipid accumulation. When cells were 
incubated in Ringer’s solution containing glucose and BCAAs, uptake occurred most 
rapidly during periods of expected high lipogenesis. Released alanine closely followed 
these patterns, suggesting BCAA catabolism. Glucose concentration did not appear to 
affect the release or uptake of BCAAs, regardless of concentration. Uptake patterns 
suggest that at increased glucose concentrations, the primary energy source for the cells is 
glucose, rather than BCAAs, even in a high-energy state. 
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 Chapter 5: Applications of Online High-Speed CE   
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 Summary 5.1
Lipogenesis was monitored using the previously developed high-speed CE assay, 
after differentiated 3T3-L1 cells were incubated with various biologically relevant 
stimuli. Two stimulants that we are particularly interested in investigating are insulin and 
artificial sweeteners. BCAA uptake was influenced by incubation with insulin or artificial 
sweeteners, while downstream metabolites were largely unaffected. Insulin’s effect on 
BCAA uptake changes based on local BCAA concentration, with increased uptake with 
larger localized BCAA concentrations. Of the artificial sweeteners assessed, acesulfame 
K+ had an amino acid release profile similar to glucose. Saccharine, aspartame, and 
fructose had less BCAA uptake than glucose, but did not generate corresponding 
decreases in downstream metabolites, as would be expected from less catabolism of 
BCAAs. Additional experiments are needed in order to clarify the impacts of insulin or 
artificial sweeteners on lipogenesis in 3T3-L1 cells.  
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 Introduction 5.2
 Effect of Insulin on Lipogenesis 5.2.1
It has been well established that BCAAs act as signaling molecules throughout the 
body and whole body BCAA concentrations are highly regulated by adipose tissue. 
29,137-
139
 Many studies have investigated the role of insulin and its relationship with obesity, 
however, the mechanism underlying the connection is still unknown. Previously, 
Cammisotto, et al. investigated the effect of insulin on the release of leptin, a prominent 
hormone related to obesity, at various glucose concentrations.
32
In their study, it was 
found that glucose was required in incubation media in order for insulin to affect leptin 
release from cells, however, the concentration of glucose (5 mM – 25 mM) did not affect 
the amount of released leptin. Throughout all of the experiments performed, it was 
obvious that insulin is a potent stimulator of leptin secretion from isolated adipocytes.
32
 
We hypothesized that other signaling molecules may be increased when adipocytes are 
incubated with insulin due to the fact that marked increases are observed in leptin 
secretion under similar conditions. Increases in leptin, operate in a negative feedback 
loop, signaling that energy is high, and it is hypothesized that this would promote 
lipogenesis. If such is the case, incubation with insulin should stimulate the uptake and 
catabolism of BCAAs and increases in downstream metabolites should be observed. 
Using the previously developed assay, we are able to measure both uptake and secretion 
of downstream metabolites as a measure of lipogenesis. 
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 Effect of Sweeteners on Lipogenesis 5.2.2
In an effort to curb obesity, many artificial sweeteners have become low-calorie 
replacements for glucose in our diets. While, at first glance, these sweeteners seemingly 
provide all of the desired benefits, sweet taste without the calories, the anti-obesity 
benefits seem to be lacking. Obesity rates have continued to increase dramatically since 
the incorporation of these artificial sweeteners in our diets.
161
 Adding artificial 
sweeteners is likely one of many factors playing an important role in the development of 
obesity, according to initial studies. 
161
 These artificial sweeteners trigger the “sweet” 
carbohydrate receptors found throughout the body and signal for anabolism to occur, but 
don’t provide the necessary calories to do so.162 As such, energy is stored and metabolism 
is reduced, thus causing weight gain, even when calorie intake is limited.
163
 Because the 
artificial sweeteners are more potent than glucose itself,
164,165
 they could lead to 
desensitization of carbohydrate receptors.
163
 In one study, saccharine was shown to be 
effective in initiating the formation of new adipocytes and promoting lipogenesis in 
mature adipocytes.
166
  
We hypothesize that if artificial sweeteners are acting on the same receptors as 
glucose and other carbohydrates, we would see a marked increase in the release of 
lipogenic markers, alanine, glutamine, and glutamate, after increased uptake of the 
BCAAs. Using our microdialysis-CE assay, we can easily detect any changes in uptake 
and secretion of metabolites to assess 3T3-L1 adipocyte response to fructose, saccharine, 
acesulfame K+ (AceK), and stevioside.  
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 Materials and Methods 5.3
 Chemicals and Reagents 5.3.1
Ciglitazone was purchased from VWR International (Radnor, Pennsylvania). α-
cyclodextrin (α-CD) was purchased from CTD Holdings, Inc. (technical grade, Alachua, 
FL). Dulbecco’s Modified Eagle’s Medium (DMEM), newborn calf serum (NCS), fetal 
bovine serum (FBS), and penicillin-streptomycin (5,000U/mL) were purchased from 
Invitrogen Molecular Probes (Eugene, OR). D-glucose, Mammalian Protein Extraction 
Reagent (M-PER®), Halt Protease Inhibitor Cocktail, EDTA free, Halt™ Phosphatase 
Inhibitor Cocktail, and sodium borate tetrahydrate were purchased from Fisher Scientific 
(Waltham, MA). 3-Isobutyl-1-methylxanthine (IBMX), dexamethasone, insulin (human), 
and all amino acids were purchased from Sigma-Aldrich (St. Louis, MO).Trypsin 
solution (0.25% Trypsin/0.53mM EDTA in Hank’s Balanced Salt Solution) was 
purchased from ATCC (Manassas, VA). Phosphate-buffered saline (PBS, 10×) was 
purchased from Bio-Rad Laboratories (Hercules, CA). 4-Fluoro-7-Nitro-2, 1, 3-
Benzoxadiazole (NBD-F) was purchased from TCI America (Portland, OR). 
 Buffers and Solutions 5.3.2
All solutions were prepared in deionized water (Milli-Q, 18.2 MΩ; Millipore, 
Bedford, MA) and filtered (0.22µm) unless otherwise noted. Stock standard solutions (1 
mM) of amino acids were prepared in Ringer’s solution. Ringer’s solution was prepared 
with 123 mM NaCl, 1.5 mM CaCl2, and 5 mM KCl, adjusted to pH 7.5; and autoclaved 
for sterilization. Ringer’s solution containing glucose (0, 5, 10, 15, and 20 mM) was 
prepared with 123 mM NaCl, 1.5 mM CaCl2, and 5 mM KCl, adjusted to pH 7.5; and 
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autoclaved for sterilization. Sheath flow buffer contained 90 mM borate adjusted to pH 
9.8. CE separation buffer contained 90 mM borate/35 mM α-cyclodextrin adjusted to pH 
9.8. Derivatization solution was prepared daily by dissolving NBD-F (4-fluoro-7-nitro-
2,1,3-benzoxadiazole; TCI America, Portland, OR) in methanol and diluting with equal 
parts 500 µM HCl and degassing under vacuum, giving a final solution of 20 mM NBD-
F/250 µM HCl in 1:1 methanol: water.  
 Cell Culture 5.3.3
3T3-L1 fibroblasts (ATCC® CL-173™) were maintained in 25 cm2 tissue culture 
flasks containing 8 mL of high glucose DMEM supplemented with 10% NCS and 1% 
penicillin/streptomycin. Cultures were maintained in a 37° C incubator (5% CO2). 3T3-
L1 cells were differentiated using methods previously described.
44
 Briefly, differentiation 
was induced by adding high glucose DMEM containing 10% FBS, 0.5 mM IBMX, 0.25 
µM dexamethasone, 2 µM ciglitazone, and 170 µM insulin. IBMX, ciglitazone, and 
dexamethasone were removed after 2 days; insulin was removed after 4 days. 
Maintenance media (high glucose DMEM, 10% FBS, and 1% penicillin/streptomycin) 
was used after 4 days. Experiments were conducted at 4 different time points—“Day 0” 
is prior to any differentiation, but confluent; “Day 2” is after 48 h of incubation with 
DMEM, FBS, IBMX, dexamethasone, ciglitazone, and insulin; “Day 4” is 96 h after 
differentiation induction, when media contains DMEM, FBS, and insulin; and finally, 
“Day14” is 14-16 days after the induction of differentiation.   
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 Measuring Bulk Amino Acid Release/Uptake 5.3.4
5.3.4.1 Insulin Experiments 
3T3-L1 cells were cultured and maintained in T25 flasks, as described above. 
Once a confluent monolayer of cells was established, differentiation was initiated. 
Experiments took place at two time points throughout the differentiation cycle, as defined 
previously. “Day 4” is 96 h after differentiation induction, when media contains DMEM, 
FBS, and insulin; “Day 14” is 14-16 days after the induction of differentiation. At each 
corresponding time point, cells were rinsed four times with Ringer’s solution containing 
5 mM glucose, 200 µM isoleucine, leucine, and valine, with or without 10 nM insulin 
(incubation medium). Cells were incubated with 1.00 mL of the corresponding incubation 
medium, for 30 min. After 30 min, the 1.00 mL of incubation medium was removed and 
500 µL of this sample was spiked with 25 µL of 1 mM D-2-amino-adipic-acid (internal 
standard), and was used for microdialysis—CE analysis. Cells were removed from the 
flask walls for protein analysis using 1.00 mL of mammalian protein extraction reagent, 
supplemented with Halt Protease Inhibitor Cocktail, EDTA free, and Halt™ Phosphatase 
Inhibitor Cocktail. Flasks incubated with this solution for 5-25 min at room temperature, 
until all cells were detached from flask walls. This 1.00 mL aliquot was collected for 
protein quantification using a bicinchoninic acid (BCA) assay. 
5.3.4.2 Sweetener Experiments 
3T3-L1 cells were cultured and maintained in T25 flasks, as described above. 
Once a confluent monolayer of cells was established, differentiation was initiated. 
Experiments were performed at “Day 4” 96 h after differentiation induction, when media 
contained DMEM, FBS, and insulin. At this time point, cells were rinsed four times with 
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Ringer’s solution containing 5 mM glucose, 200 µM isoleucine, leucine, and valine. Cells 
were then incubated with 1.00 mL of one of five sweetener solutions, as described above, 
for 30 min. After 30 min, the 1.00 mL of the sweetener solution  was removed and 500 
µL of this sample was spiked with 25 µL of 1 mM D-2-amino-adipic-acid (internal 
standard), and was used for microdialysis—CE analysis. Cells were removed from the 
flask walls for protein analysis using 1.00 mL of mammalian protein extraction reagent, 
supplemented with Halt Protease Inhibitor Cocktail, EDTA free, and Halt™ Phosphatase 
Inhibitor Cocktail for 5-25 min at room temperature. This 1.00 mL aliquot was collected 
for protein quantification using a bicinchoninic acid (BCA) assay. 
 Microdialysis probes 5.3.5
Microdialysis probes were constructed in-house using a side-by-side geometry, as 
described previously
131
. Briefly, two 40 µm i.d. x 105 µm o.d. fused silica capillaries 
(Polymicro Technologies, Phoenix, AZ) were inserted into a 200 µm i.d. piece of hollow 
fiber dialysis tubing made from regenerated cellulose (13 kD MWCO, Spectrum 
Laboratories, Inc., Rancho Dominguez, CA). A sampling region was created by offsetting 
the capillaries by 1 cm, and sealing using polyimide resin (Alltech, Deerfield, IL). Probes 
were conditioned prior to use by flushing with ethanol (45µL/h) for five min, followed by 
ten min of Ringer’s solution (25µL/h). Probes were perfused with Ringer’s solution at 25 
µL/h throughout experiments. 
 Online Derivatization  5.3.6
Dialysate was carried in a 30-40 cm long × 40 µm i.d. × 360 µm o.d. fused silica 
capillary to a 250 µm i.d. stainless steel cross (Valco Instruments Co. Inc, Houston, TX) 
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where it was mixed with a 5 µL/h stream of borate buffer and a 5 µL/h stream of 
derivatization solution. The derivatization of primary and secondary amines took place as 
the dialysate mixture traveled through a 90 cm long, 75 µm i.d. × 360 µm o.d. fused silica 
capillary from the reaction cross to the flow gate interface; 66 cm of this capillary was 
heated to accelerate the reaction by passing through flexible tubing that was circulating 
water from a water bath at 80°C (NESLAB EX-7 Digital One heating bath circulator, 
Thermo, Newington, NH). The length of the reaction capillary and flow rates used 
resulted in a 5 min reaction time, allowing the labeling reaction to go to completion.
90
 
 High Speed Capillary Electrophoresis  5.3.7
An 8-8.5 cm long, 10 µm i.d. × 360 µm o.d. fused silica capillary (separation 
capillary) was aligned coaxially, with a 50 µm gap, with the reaction capillary in  a 
polycarbonate flow gate interface block.
73
 A syringe pump (Pump 22 syringe pump, 
Harvard Apparatus, Holliston, MA) pumped separation buffer at 40 mL/hthrough this 
gap. Separation buffer flow was controlled by a pneumatically actuated valve (C2-300A 
10 port valve, Valco Instruments Co. Inc., Houston, TX); crossflow of the separation 
buffer was stopped to for 500 ms allowing a sample plug to build up in the gap. An 
injection voltage of -13 kV was applied to the exit of the separation capillary for 200 ms. 
The flow stream though the flow gate was resumed and a separation voltage of -19 kV 
was applied. Separations were performed every 30 s. Injections were controlled by an in-
house LabVIEW program.  
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 LIF Detection  5.3.8
A 488 nm argon ion laser was used for LIF detection (150 mW, Melles Griot, 
Carlsbad, CA). The laser beam was passed through a 10× beam expander (Edmond 
Optics, Barrington, NJ), and focused using a 1× lens to a point just past the exit of the CE 
separation capillary in a fused-silica sheath flow cuvette(2 mm square with a 400 µm × 
400 µm square inner bore).
82,135
 Fluorescence emission is collected at 90° with a  60×, 0.7 
NA long working distance objective (Universe Kogaku, Oyster Bay, NJ) and filtered 
through spatial (~1 mm diameter) and bandpass filters (543.5 ± 10 nm) (Melles Griot, 
Irvine, CA), and recorded using a photomultiplier tube (PMT R1477, Hamamatsu Corp., 
Bridgewater, NJ). Current from the PMT was amplified (Keithley 428 Current Amplifier, 
Keithley Instruments Inc., Cleveland, OH), filtered with a 10 ms rise time, and recorded 
using a data acquisition card (National Instruments Corp., Austin, TX). Data analysis was 
performed using Cutter Analysis 7.0.
149
 
 Bicinchoninic Acid (BCA) Assay 5.3.9
Amino acid concentrations were normalized according to cell protein content, as 
measured using a BCA assay. A Pierce™ BCA Protein Assay Kit was used according to 
included instructions. Briefly, working reagent was prepared by combining “Reagent A” 
and “Reagent B” in a ratio of 50:1 (A: B). 25 µL of each sample or standard was pipetted 
into individual wells of a 96 well plate followed by 200 µL of working reagent; all 
samples were analyzed in triplicate. The plate was gently shaken for 30 s to ensure 
mixing of the working reagent and samples. After shaking, the plate was incubated at 
37°C for 30 min. After incubation, the plate was removed from the incubator and 
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absorbance at 562 nm was measured using a plate reader (Spectromax Plus; Molecular 
Devices, LLC, Sunnyvale, CA). A calibration curve was generated from BSA standards. 
Using this standard curve, protein content for each flask was determined and used for 
normalizing amino acid signals obtained from CE separation. 
 Bicinchoninic Acid (BCA) Assay 5.3.10
Amino acid concentrations were normalized according to cell protein content, as 
measured using a BCA assay. A Pierce™ BCA Protein Assay Kit was used according to 
included instructions. Briefly, working reagent was prepared by combining “Reagent A” 
and “Reagent B” in a ratio of 50:1 (A: B). 25 µL of each sample or standard was pipetted 
into individual wells of a 96 well plate followed by 200 µL of working reagent; all 
samples were analyzed in triplicate. The plate was gently shaken for 30 s to ensure 
mixing of the working reagent and samples. After shaking, the plate was incubated at 
37°C for 30 min. After incubation, the plate was removed from the incubator and 
absorbance at 562 nm was measured using a plate reader (Spectromax Plus; Molecular 
Devices, LLC, Sunnyvale, CA). A calibration curve was generated from BSA standards. 
Using this standard curve, protein content for each flask was determined and used for 
normalizing amino acid signals obtained from CE separation. 
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 Results and Discussion 5.4
 Effect of Insulin on Lipogenesis 5.4.1
Previous studies have shown that insulin influences the release of leptin and other 
important chemicals found in 3T3-L1 cells. We hypothesized that insulin would also 
influence the rate of uptake of BCAAs, promoting lipogenesis in 3T3-L1 adipocytes. 
Using the techniques presented here, one could imagine culturing the cells and incubating 
them with various concentrations of insulin, to see how the presence of insulin affects 
lipogenesis. 
Figure 5.1. Uptake of BCAAs on Day 4 when incubated in Ringer’s solution with 
(red) and without (black) 10 nM insulin, 5 mM glucose, and either 40, 200, or 1000 
µM BCAAs for 30 minutes. Error bars are SEM; n=3. 
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 As shown in Figure 5.1, a range of BCAA concentrations were investigated, 
along with incubation with or without 10 nM insulin. 10 nM insulin was chose as the 
incubation concentration as it correlates with normal circulating concentrations found in 
mice plasma. The effect of influence of insulin on the uptake of BCAAs, depends on 
local BCAA concentration, as shown in Figure 5.1 Isoleucine uptake changes as a 
function of both 
incubated BCAA 
concentration and 
insulin presence. At 
lower 
concentrations of 
BCAAs (40µm), 
3T3-L1 cells had 
less uptake when 
insulin is present 
(red). This trend is 
observed for all 3 
BCAAs. However, 
when BCAA concentrations are increased to a biological concentration (200 µM), 
isoleucine has more uptake when insulin is present (red), while leucine and valine do not. 
At high concentrations (1 mM), all three BCAAs show increased uptake of BCAAs when 
incubated with insulin (red), compared to without insulin (black). This could be due to 
Figure 5.2. Release of alanine and glutamine on Day 4 when 
incubated in Ringer’s solution with (red) and without (black) 10 
nM insulin, 5 mM glucose, and either 40, 200, or 1000 µM BCAAs 
for 30 minutes. Error bars are SEM; n=3. 
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localization of insulin receptors on the outer cell membrane to promote the uptake of 
glucose into the cells, rather than BCAAs.  
Downstream release of alanine and glutamine remains largely unchanged when 
comparing the release profiles in the presence of insulin, no matter the BCAA 
concentration, as shown in Figure 5.2. In fact, the trend at 1000 µM shows less release of 
lipogenic marker alanine, in the presence of 10 nM insulin. Because this trend was 
unexpected, the experiment was repeated once the cells reached the fully mature state, on 
Day 14. This was done to investigate whether insulin’s effect on 3T3-L1 cells is the 
same, no matter what maturation stage the cells are in. Figure 5.3Error! Reference 
source not found.shows the uptake of BCAAs when incubated with Ringer’s solution, 5 
Figure 5.3. Uptake of BCAAs on Day 14 when incubated in Ringer’s solution with 
(red) and without (black) 10 nM insulin, 5 mM glucose, and either 40, 200, or 1000 
µM BCAAs for 30 minutes. Error bars are SEM; n=3 
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mM glucose, BCAAS (40, 200, o4 1000 µM), with or without insulin. Similar trends to 
those seen on Day 4 are observed for both the BCAAs (Figure 5.3) and downstream 
lipogenic markers (Figure 5.4).Figure 5.4 shows that as BCAA concentration is 
increased, release of alanine, and glutamine increases, regardless of insulin presence. 
Using the developed assay, additional exploration about insulin’s role in lipogenesis in 
3T3-L1 adipocytes can be conducted. The high-throughput nature of the assay allows for 
multiple conditions to be analyzed quickly when analyzing information from bulk cell 
culture. 
 
 
 
Figure 5.4. Release of alanine, glutamine on Day 4 when incubated in Ringer’s 
solution with (red) and without (black) 10 nM insulin, 5 mM glucose, and either 
40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are SEM; n=3 
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 Effect of Artificial Sweeteners on Lipogenesis 5.4.2
As shown in Figure 5.5(orange), when 3T3-L1 cells are incubated on Day 4with 
the maximum daily allowance of fructose and 5 mM glucose, uptake of the BCAAs is 
diminished, compared to the uptake when incubated with only 5 mM glucose (Figure 5.5, 
black). The downstream metabolites, however, have no significant change in release, as 
shown in Figure 5.6. This suggests that BCAAs are not participating in lipogenesis and 
may suggest that fructose is a more preferred energy source for differentiating adipocytes 
over BCAAs. The maximum daily allowance was converted to a concentration for each 
sweetener, using average blood volume and weight of a mouse. The presence of AceK, in  
Figure 5.5. Uptake of BCAAs on Day 4 when incubated in Ringer’s solution, 200 
µM BCAAs, and and either glucose (5 mM, black), or 5 mM glucose plus one of the 
following: stevioside (64.5µM, red), saccharin (350 µM, green), AceK (968 µM, 
blue), or fructose (30 mM, orange). Error bars are SEM; n = 3 samples. . *, p-value 
< 0.05, **, p-value < 0.01 compared to incubation with 5 mM glucose only. 
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addition to 5 mM glucose, however, does not change, statistically, the amount of BCAAs 
that are taken into the cells (Figure 5.5, blue). Isoleucine and leucine see the highest 
uptake of BCAAs when incubated with 5 mM glucose only (Figure 5.5, black), while 
valine is taken into the cells the most when incubated with AceK and 5 mM glucose. 
Interestingly, the downstream metabolites, alanine, glutamine, and glutamate, as shown 
in Figure 5.6, do not have increased release with corresponding BCAA uptake. Another 
interesting discovery is that incubation with stevioside and 5 mM glucose did not 
Figure 5.6. Release of alanine, glutamine, and glutamate on Day 4 when incubated in 
Ringer’s solution, 200 µM BCAAs, and either glucose (5 mM, black), or 5 mM glucose 
plus one of the following: stevioside (64.5µM, red), saccharin (350 µM, green), AceK 
(968 µM, blue), or fructose (30 mM, orange) for 30 minutes. Error bars are SEM; n = 3 
samples. *, p-value < 0.05, **, p-value < 0.01 compared to incubation with 5 mM 
glucose only. 
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promote uptake of BCAAs (Figure 5.5, red), but did however, promote the release of 
glutamate (Figure 5.6, red) compared to control.  
  Conclusions 5.5
The previously developed assay was used for monitoring changes in lipogenesis 
due to the presence of insulin or artificial sweeteners. As demonstrated, local BCAA 
concentration appears to have more influence on lipogenesis than presence of insulin, 
especially at circulating concentrations of BCAAs. At high concentrations of BCAAs, 
insulin may have an effect on uptake and lipogenesis in 3T3-L1 cells. Further 
investigation into this observation is necessary as trends vary depending on BCAA 
concentration.  
Additional examination of the trends observed through incubation of 3T3-L1 cells 
with 5 mM glucose, 200 µM BCAAs, and the maximum daily allowed intake for each the 
four sweeteners is needed in order to make concrete conclusions about how the 
sweeteners affect lipogenesis. This data suggests that both AceK and fructose may be 
affecting the uptake of BCAAs in 3T3-L1 adipocytes. While AceK shows BCAA levels 
similar to 5 mM glucose control groups, fructose diminishes the uptake of BCAAs. 
Investigation into the lipogenic markers indicates that there could possibly be an increase 
in lipogenesis when AceK is present, due to increased release of alanine, glutamine. 
Although fructose diminishes BCAA uptake, downstream lipogenic metabolites remain at 
levels similar to control. This result suggests that fructose may interfere with BCAA 
receptor, blocking their uptake. In either study, it may be useful for the development of 
sampling method that allows for faster temporal information. Many cellular responses are 
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fast, so trends may not be observable when experiments are performed every 30 min. 
Thus, development of a way to sample 3T3-L1 cells on a faster time-scale is needed.   
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 Chapter 6: Summary and Future Applications  
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 Summary  6.1
In Chapter 2, we described the development of a high-speed CE assay coupled 
with microdialysis for the separation and detection of BCAAs. Assay optimization was 
achieved through careful manipulation of buffer components in order to obtain the best 
separation of the analytes of interest. LODs of 100-400 nM were achieved for the 
BCAAs, with 100,000-215,000 theoretical plates easily obtained. As a proof of concept 
experiment, release and uptake profiles of 3T3-L1 cells were monitored. Cells were 
incubated with 200 µM BCAAs and 5 mM glucose in Ringer’s solution for varying 
amounts of time, in order to see changes in the rate of uptake of BCAAs and release of 
downstream metabolites, alanine, glutamine, and glutamate. The rate of release of 
downstream metabolites stabilized after ~30 min, while BCAA uptake continued to slow 
over the course of an h. Because downstream release stabilized after 30 min, all future 
experiments would be based off of this time, a balance between experimental time and 
detectable signal. This result was exciting and important because it provided information 
about the speed of uptake catabolism of BCAAs in 3T3-L1 cells and corresponding 
downstream metabolite release. The development of this high-throughput assay allows 
for rapid sample throughput, providing large amounts of data that was unknown 
previously.  
In Chapter 3, further investigation into how local concentrations of BCAAs affect 
cells throughout the differentiation process. 3T3-L1 cells are differentiated into mature 
adipocytes over the course of ~14 days. Experiments were conducted when a media 
formulation change induced a physiological change in the cells throughout this process: 
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on Day 0, Day 2, Day 4, and Day 14. At each of these days, flasks were incubated with or 
without circulating concentrations of BCAAs, in order to see if there was a change in the 
metabolism of BCAAs, monitored through the downstream release of alanine, glutamine, 
and glutamate, at each time point. It was found that BCAA release was lowest during 
periods of presumed increased lipogenesis, Days 2 and 4, and uptake of BCAAS was 
highest during those same time periods. Once cells reached a fully mature state, both 
release and uptake slowed. Alanine, glutamine, and glutamate release profiles supported 
these trends, with increased release during later stages of maturation. These trends 
demonstrate that the presence of BCAAs stimulates lipogenesis in 3T3-L1 cells. 
Understanding the effects of BCAAs on lipogenesis throughout development of cells 
provides insight into the development of dysregulation of metabolic diseases.  
In Chapter 4, we probed the effects of glucose and BCAAs on lipogenesis 
throughout the development of 3T3-L1 cells even further. In order to do so, 3T3-L1 cells 
were incubated with or without 200 µM BCAAS, with varying concentrations of glucose 
(0 mM – 20 mM), in Ringer’s solution.  The goal of these experiments was to see if 
different trends were observed in BCAA catabolism, based on local concentrations of 
glucose or BCAAs, as both are known to be energy sources for cells. 3T3-L1 cells 
undergo lipogenesis most rapidly on Day 4 of differentiation, and trends observed at all 
glucose concentrations supported these trends. There were no statistical differences in 
BCAA uptake or release based on local glucose concentration. There were also no 
observed statistical differences in downstream lipogenesis markers based on local glucose 
trends. There were, however, changes in the release of downstream lipogenesis markers, 
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based on the presence of BCAAs. These trends could be due to the fact that 3T3-L1 cells 
have few glucose receptors located on the cellular membrane, until they are localized 
there by insulin. It could also be due to the ease of uptake of BCAAs to generate TCA 
cycle intermediates, rather than taking in glucose for glycolysis. The breakdown of 
BCAAs may be more energetically favorable than to glycolysis.  
In Chapter 5, preliminary analysis of biological stimuli and their effects on 
lipogenesis in 3T3-L1 cells was assessed. Using the developed assay, we observed trends 
that are inconclusive as to the role that insulin plays in relation to BCAA uptake and 
lipogenesis. Trends observed when 3T3-L1 cells were incubated with varying artificial 
and natural sweeteners were also inconclusive. Changes in BCAA uptake were not 
reflected in downstream lipogenesis markers. Further investigations into both of these 
phenomena through optimization of incubation media as well as expanded concentrations 
of stimuli provide the opportunity to learn and understand how they affect lipogenesis in 
cells.  
 Future Applications 6.2
Microdialysis coupled to high-speed CE is an analytical tool that can be used to 
study many different biological systems and provide answers to many unanswered 
biological questions. The work presented in this thesis has demonstrated the ability to 
generate vast amounts of data, using a high-throughput assay. While obesity is a disease 
that has been around for many decades, many basic questions still remain about the 
development of the disease. Many experiments to assess the development of disease are 
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tedious and data collection is slow; using the assay developed in this work can help speed 
up the data collection process.  
 Modifying the sampling platform 6.2.1
In Chapter 2, we demonstrated the high-speed CE assay and its usefulness as a 
high-throughput sampling method. Rather than using the assay for high-throughput 
sampling of fractions collected from bulk culture, the assay could be used online, in 
conjunction with the profusion chamber, in order to obtain temporal information, 
approximately every 30 s about any in vitro cell model of interest. In particular, obtaining 
information about 3T3-L1 cells on this time scale will provide insight into the 
mechanisms of lipogenesis that are otherwise unattainable.  
Previously, microdialysis sampling was using in combination with a perfusion 
Figure 6.1. Image of profusion chamber device. The top part was 3D printed in order 
to fit well into the bottom polycarbonate device. A microdialysis probe is inserted 
into a channel (right) with inlet (left) and outlet (bottom) tubing connecting the device 
to the online high-speed CE system. 
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chamber in order to analyze amines released from salamander retinas.
134
 Using this 
device, isolated larval salamander retinas were mounted in the perfusion chamber and 
perfused with Ringer’s solution. Potassium stimulations were performed and amines were 
monitored using high-speed CE after OPA derivatization.  
Using this perfusion chamber device, in conjunction with in vitro cell models, 
provides an opportunity to obtain near real-time information about cellular processes. To 
do so, cells can be grown directly on the top portion of the device, shown in Figure 6.1. 
Figure 6.2. Temporal response of the in vitro microdialysis CE instrument following a 5 
minute stiumatio nof 3T3-L1 adipocyteswith 10 nM insulin. Injections were made every 
30 seconds. Top trace is isoleucine (black) and bottom trace is glutamine (red). These two 
are presented in order to demonstrate the utility of the profusion chamber device and it’s 
ability to monitor fast changes in cellular response.Delay between simulation and 
increased peak height is due to the time it takes the sample to reach the detector. 
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 As proof of concept, 3T3-L1 cells were cultured and differentiated on the top of 
the device. The device was assembled and basal levels of released amino acids were 
monitored. As shown in Figure 6.2, when a stimulation of 10 nM insulin was applied for 
5 min, you can see the observed change in peak intensities. Glutamine release (red) 
increases with corresponding decreases in isoleucine uptake (black, indicated by a 
decrease in peak intensity). Further optimization of flow rates through the chamber, as 
well as culturing techniques will provide a useful platform for culturing cells that are 
unable to be cultured directly onto microdialysis probes. Attempts were made to use this 
technique,
115
 however 3T3-L1 cell bodies are too large to adhere well to the probe’s 
curved surface. 
In order to efficiently optimize culturing surface parameters, 3D printing could be 
employed. 3D printing provides fast turn-around and output for design changes, as well 
as giving the profusion chamber device a “one-time use” capability, which is often 
desired when using in vitro sampling methods. The top portion of the device can simply 
be thrown away after use because top pieces can be printed in an efficient, cost effective 
manner. Ultimately, an entire device (both top and bottom) could be printed, depending 
on the abilities of the 3D printer involved.  
Another useful application of the separation conditions employed throughout this 
thesis work would be to couple the CE separation mode to a second dimension. Previous 
work in our group has improved peak capacity by coupling nLC to micro-free flow 
electrophoresis (µFFE)
167
 to separate complex samples. Coupling CE to µFFE would 
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allow for the separation of amino acids that cannot fully be resolved using the current 
assay (ex. valine, citrulline), while still maintaining a high-throughput system. 
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 Appendix 
 
Figure A.1. Net rate of lysine, ornithine, and threonine efflux by 3T3-L1 cells incubated 
with Ringer’s solution + 5 mM glucose and 200 µM isoleucine, leucine and valine for 
time periods ranging from 5 to 60 minutes. Rates were normalized to cell protein content 
as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.2. Net rate of β-alanine, taurine, and aspartate efflux by 3T3-L1 cells incubated 
with Ringer’s solution + 5 mM glucose and 200 µM isoleucine, leucine and valine for 
time periods ranging from 5 to 60 minutes. Rates were normalized to cell protein content 
as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.3. Net rate of histidine, GABA, and glycine efflux by 3T3-L1 cells incubated 
with Ringer’s solution + 5 mM glucose and 200 µM isoleucine, leucine and valine for 
time periods ranging from 5 to 60 minutes. Rates were normalized to cell protein content 
as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.4. Net rate of phenylalanine efflux by 3T3-L1 cells incubated with Ringer’s 
solution + 5 mM glucose and 200 µM isoleucine, leucine and valine for time periods 
ranging from 5 to 60 minutes. Rate was normalized to cell protein content as determined 
by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.5. Rate of isoleucine, leucine, and valine release at each stage of differentiation 
by 3T3-L1 cells incubated with Ringer’s solution, 200 µM BCAAs, and varying 
concentrations of glucose. Rates were normalized to cell protein content as determined by 
BCA assay. Error bars are SE for n=3 samples. 
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Figure A.6 . Rate of isoleucine, leucine, and valine uptake after incubation with varying 
concentrations of glucose, at each stage of differentiation by 3T3-L1 cells incubated with 
Ringer’s solution, 200 µM BCAAs, and varying concentrations of glucose. Rates were 
normalized to cell protein content as determined by BCA assay. Error bars are SE for n=3 
samples. 
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Figure A.7. Rate of alanine, glutamate, and glutamine release at each stage of 
differentiation after incubation with varying concentrations of glucose by 3T3-L1 cells 
incubated with Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and 
varying concentrations of glucose (0-20 mM). Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.8. Rate of alanine, glutamate, and glutamine release after incubation with 
varying concentrations of glucose, at each stage of differentiation, by 3T3-L1 cells 
incubated with Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and 
varying concentrations of glucose (0-20 mM). Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.9. Rate of isoleucine, leucine, and valine uptake at each stage of differentiation 
by 3T3-L1 cells incubated with Ringer’s solution, 200 µM BCAAs, and varying 
concentrations of glucose. Rates were normalized to cell protein content as determined by 
BCA assay. Error bars are SE for n=3 samples. 
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Figure A.10. Rate of isoleucine, leucine, and valine uptake after incubation with varying 
concentrations of glucose, at each stage of differentiation by 3T3-L1 cells incubated with 
Ringer’s solution, 200 µM BCAAs, and varying concentrations of glucose. Rates were 
normalized to cell protein content as determined by BCA assay. Error bars are SE for n=3 
samples. 
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Figure A.11. Rate of aspartate, β-alanine, and GABA release after incubation with 
varying concentrations of glucose, at each stage of differentiation, by 3T3-L1 cells 
incubated with Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and 
varying concentrations of glucose (0-20 mM). Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.12. Rate of aspartate, β- alanine, and GABA release at each stage of 
differentiation after incubation with varying concentrations of glucose by 3T3-L1 cells 
incubated with Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and 
varying concentrations of glucose (0-20 mM). Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.13. Rate of glycine, histidine, and lysine release after incubation with varying 
concentrations of glucose, at each stage of differentiation, by 3T3-L1 cells incubated with 
Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and varying 
concentrations of glucose (0-20 mM). Amounts were normalized to cell protein content 
as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.14. Rate of glycine, histidine, and lysine release at each stage of differentiation 
after incubation with varying concentrations of glucose by 3T3-L1 cells incubated with 
Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and varying 
concentrations of glucose (0-20 mM). Amounts were normalized to cell protein content 
as determined by BCA assay. Error bars are SE for n=3 samples. 
  136 
 
Figure A.15 Rate of methionine, ornithine, and phenylalanine release after incubation 
with varying concentrations of glucose, at each stage of differentiation, by 3T3-L1 cells 
incubated with Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and 
varying concentrations of glucose (0-20 mM). Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.16 Rate of methionine, ornithine, and phenylalanine release at each stage of 
differentiation after incubation with varying concentrations of glucose by 3T3-L1 cells 
incubated with Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and 
varying concentrations of glucose (0-20 mM). Amounts were normalized to cell 
protein content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.17. Rate of taurine and threonine release after incubation with varying 
concentrations of glucose, at each stage of differentiation, by 3T3-L1 cells incubated 
with Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and varying 
concentrations of glucose (0-20 mM). Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.18. Rate taurine and threonine release at each stage of differentiation after 
incubation with varying concentrations of glucose by 3T3-L1 cells incubated with 
Ringer’s solution, with (red) and without (black) 200 µM BCAAs, and varying 
concentrations of glucose (0-20 mM). Amounts were normalized to cell protein 
content as determined by BCA assay. Error bars are SE for n=3 samples. 
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Figure A.19. Release of threonine (Thr) and taurine (Tau) on Day 4 when incubated in 
Ringer’s solution with (red) and without (black) 10 nM insulin, 5 mM glucose, and either 
40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are SEM; n=3. 
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Figure A.20. Release of threonine (Thr) and taurine (Tau) on Day 14 when incubated in 
Ringer’s solution with (red) and without (black) 10 nM insulin, 5 mM glucose, and either 
40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are SEM; n=3 
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Figure A.21. Release of aspartate (Asp), β-alanine (b-Ala), and GABA on Day 4 when 
incubated in Ringer’s solution with (red) and without (black) 10 nM insulin, 5 mM 
glucose, and either 40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are SEM; 
n=3. 
 
  143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.22. . Release of β-alanine (b-Ala), and GABA on Day 14 when incubated in 
Ringer’s solution with (red) and without (black) 10 nM insulin, 5 mM glucose, and either 
40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are SEM; n=3 
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Figure A.23. Release of glycine (Gly), lysine (Lys), and ornithine (Orn) on Day 4 when 
incubated in Ringer’s solution with (red) and without (black) 10 nM insulin, 5 mM 
glucose, and either 40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are SEM; 
n=3. 
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Figure A.24. . Release of glycine (Gly), lysine (Lys), and ornithine (Orn) on Day 14 
when incubated in Ringer’s solution with (red) and without (black) 10 nM insulin, 5 mM 
glucose, and either 40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are SEM; n=3 
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Figure A.25. Release of phenylalanine (Phe), methionine (Met), and histidine (His) on 
Day 4 when incubated in Ringer’s solution with (red) and without (black) 10 nM insulin, 
5 mM glucose, and either 40, 200, or 1000 µM BCAAs for 30 minutes. Error bars are 
SEM; n=3. 
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Figure A.26. . Release phenylalanine (Phe), methionine (Met), and histidine (His) on 
Day 14 when incubated in Ringer’s solution with (red) and without (black) 10 nM 
insulin, 5 mM glucose, and either 40, 200, or 1000 µM BCAAs for 30 minutes. Error bars 
are SEM; n=3 
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Figure A.27 Release of ornithine (Orn), phenylalanine (Phe), and methionine (Met) on 
Day 4 when incubated in Ringer’s solution, 200 µM BCAAs, and either glucose (5 mM, 
black), or 5 mM glucose plus one of the following: stevioside (64.5µM, red), saccharin 
(350 µM, green), AceK (968 µM, blue), or fructose (30 mM, orange) for 30 minutes. 
Error bars are SEM; n = 3 samples. *, p-value < 0.05, **, p-value < 0.01 compared to 
incubation with 5 mM glucose only (black). 
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Figure A.28 Release of taurine (Tau), histidine (His), and tyrosine (Tyr) on Day 4 when 
incubated in Ringer’s solution, 200 µM BCAAs, and either glucose (5 mM, black), or 5 
mM glucose plus one of the following: stevioside (64.5µM, red), saccharin (350 µM, 
green), AceK (968 µM, blue), or fructose (30 mM, orange) for 30 minutes. Error bars are 
SEM; n = 3 samples. *, p-value < 0.05, **, p-value < 0.01 compared to incubation with 5 
mM glucose only (black). 
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Figure A.29. Release of threonine (Thr), glycine (Gly), and lysine (Lys) on Day 4 when 
incubated in Ringer’s solution, 200 µM BCAAs, and either glucose (5 mM, black), or 5 
mM glucose plus one of the following: stevioside (64.5µM, red), saccharin (350 µM, 
green), AceK (968 µM, blue), or fructose (30 mM, orange) for 30 minutes. Error bars are 
SEM; n = 3 samples. *, p-value < 0.05, **, p-value < 0.01 compared to incubation with 5 
mM glucose only (black). 
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Figure A.30. Release of β-alanine (b-Ala) on Day 4 when incubated in Ringer’s solution, 
200 µM BCAAs, and either glucose (5 mM, black), or 5 mM glucose plus one of the 
following: stevioside (64.5µM, red), saccharin (350 µM, green), AceK (968 µM, blue), or 
fructose (30 mM, orange) for 30 minutes. Error bars are SEM; n = 3 samples. *, p-value 
< 0.05, **, p-value < 0.01 compared to incubation with 5 mM glucose only (black). 
